Inhibition	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
replication	O
by	O
a	O
Tat-activated	B-DNA
,	I-DNA
transduced	I-DNA
interferon	I-DNA
gene	I-DNA
:	O
targeted	O
expression	O
to	O
human	B-cell_type
immunodeficiency	I-cell_type
virus	I-cell_type
type	I-cell_type
1-infected	I-cell_type
cells	I-cell_type
.	O

We	O
have	O
examined	O
the	O
feasibility	O
of	O
using	O
interferon	B-protein
(	O
IFN	B-protein
)	O
gene	O
transfer	O
as	O
a	O
novel	O
approach	O
to	O
anti-human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
therapy	O
in	O
this	O
study	O
.	O

To	O
limit	O
expression	O
of	O
a	O
transduced	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	I-DNA
LTR	I-DNA
)	I-DNA
-IFNA2	I-DNA
(	O
the	O
new	O
approved	O
nomenclature	O
for	O
IFN	B-DNA
genes	I-DNA
is	O
used	O
throughout	O
this	O
article	O
)	O
hybrid	B-DNA
gene	I-DNA
to	O
the	O
HIV-1-infected	B-cell_line
cells	I-cell_line
,	O
HIV-1	B-DNA
LTR	I-DNA
was	O
modified	O
.	O

Deletion	O
of	O
the	O
NF-kappa	B-DNA
B	I-DNA
elements	I-DNA
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
significantly	O
inhibited	O
Tat	B-protein
-mediated	O
transactivation	O
in	O
T-cell	B-cell_line
lines	I-cell_line
,	O
as	O
well	O
as	O
in	O
a	O
monocyte	B-cell_line
line	I-cell_line
,	O
U937	B-cell_line
.	O

Replacement	O
of	O
the	O
NF-kappa	B-DNA
B	I-DNA
elements	I-DNA
in	O
the	O
HIV-1	B-DNA
LTR	I-DNA
by	O
a	O
DNA	B-DNA
fragment	I-DNA
derived	O
from	O
the	O
5'-flanking	B-DNA
region	I-DNA
of	O
IFN-stimulated	B-DNA
gene	I-DNA
15	I-DNA
(	O
ISG15	B-DNA
)	O
,	O
containing	O
the	O
IFN-stimulated	B-DNA
response	I-DNA
element	I-DNA
,	O
partially	O
restored	O
Tat	B-protein
-mediated	O
activation	O
of	O
LTR	B-DNA
in	O
T	B-cell_type
cells	I-cell_type
as	O
well	O
as	O
in	O
monocytes	B-cell_type
.	O

Insertion	O
of	O
this	O
chimeric	B-DNA
promoter	I-DNA
(	O
ISG15	B-DNA
LTR	I-DNA
)	O
upstream	O
of	O
the	O
human	B-DNA
IFNA2	I-DNA
gene	I-DNA
directed	O
high	O
levels	O
of	O
IFN	B-protein
synthesis	O
in	O
Tat-expressing	B-cell_line
cells	I-cell_line
,	O
while	O
this	O
promoter	O
was	O
not	O
responsive	O
to	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
-mediated	O
activation	O
.	O

ISG15-LTR-IFN	B-DNA
hybrid	I-DNA
gene	I-DNA
inserted	O
into	O
the	O
retrovirus	B-DNA
vector	I-DNA
was	O
transduced	O
into	O
Jurkat	B-cell_line
and	O
U937	B-cell_line
cells	I-cell_line
.	O

Selected	O
transfected	B-cell_line
clones	I-cell_line
produced	O
low	O
levels	O
of	O
IFN	B-protein
A	I-protein
(	O
IFNA	B-protein
)	O
constitutively	O
,	O
and	O
their	O
abilities	O
to	O
express	O
interleukin-2	B-protein
and	O
interleukin-2	B-protein
receptor	I-protein
upon	O
stimulation	O
with	O
phytohemagglutinin	B-protein
and	O
phorbol	O
myristate	O
acetate	O
were	O
retained	O
.	O

Enhancement	O
of	O
IFNA	B-protein
synthesis	O
observed	O
upon	O
HIV-1	O
infection	O
resulted	O
in	O
significant	O
inhibition	O
of	O
HIV-1	O
replication	O
for	O
a	O
period	O
of	O
at	O
least	O
30	O
days	O
.	O

Virus	O
isolated	O
from	O
IFNA-producing	B-cell_line
cells	I-cell_line
was	O
able	O
to	O
replicate	O
in	O
the	O
U937	B-cell_line
cells	I-cell_line
but	O
did	O
not	O
replicate	O
efficiently	O
in	O
U937	B-cell_line
cells	I-cell_line
transduced	O
with	O
the	O
IFNA	B-DNA
gene	I-DNA
.	O

These	O
results	O
suggest	O
that	O
targeting	O
IFN	B-protein
synthesis	O
to	O
HIV-1-infected	B-cell_line
cells	I-cell_line
is	O
an	O
attainable	O
goal	O
and	O
that	O
autocrine	O
IFN	B-protein
synthesis	O
results	O
in	O
a	O
long-lasting	O
and	O
permanent	O
suppression	O
of	O
HIV-1	O
replication	O
.	O

JOURNAL	NULL
or	NULL
ViRoLOGY	NULL
,	NULL
Jan.	NULL
1995	NULL
,	NULL
p.	NULL
110-121	NULL
0022-538	NULL
X/95/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
©	NULL
1995	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

69	NULL
,	NULL
No	NULL
.	NULL

1	NULL
Inhibition	NULL
of	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
Type	NULL
1	NULL
Replication	NULL
by	NULL
a	NULL
Tat-Activated	NULL
,	NULL
Transduced	NULL
Interferon	NULL
Gene	NULL
:	NULL
Targeted	NULL
Expression	NULL
to	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
Type	NULL
1-Infected	NULL
Cells	NULL
YEU	NULL
SU	NULL
,	NULL
'¢	NULL
WALDEMAR	NULL
POPIK	NULL
,	NULL
'	NULL
anp	NULL
PAULA	NULL
M.	NULL
PITHA	NULL
``	NULL
``	NULL
*	NULL
Oncology	NULL
Center	NULL
'	NULL
and	NULL
Department	NULL
of	NULL
Molecular	NULL
Biology	NULL
and	NULL
Genetics	NULL
,	NULL
``	NULL
The	NULL
Johns	NULL
Hopkins	NULL
University	NULL
,	NULL
Baltimore	NULL
,	NULL
Maryland	NULL
21231	NULL
Received	NULL
23	NULL
May	NULL
1994/Accepted	NULL
13	NULL
October	NULL
1994	NULL
We	NULL
have	NULL
examined	NULL
the	NULL
feasibility	NULL
of	NULL
using	NULL
interferon	NULL
(	NULL
IFN	NULL
)	NULL
gene	NULL
transfer	NULL
as	NULL
a	NULL
novel	NULL
approach	NULL
to	NULL
anti-human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
therapy	NULL
in	NULL
this	NULL
study	NULL
.	NULL

To	NULL
limit	NULL
expression	NULL
of	NULL
a	NULL
transduced	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
-IFNA2	NULL
(	NULL
the	NULL
new	NULL
approved	NULL
nomenclature	NULL
for	NULL
IFN	NULL
genes	NULL
is	NULL
used	NULL
throughout	NULL
this	NULL
article	NULL
)	NULL
hybrid	NULL
gene	NULL
to	NULL
the	NULL
HIV-1-infected	NULL
cells	NULL
,	NULL
HIV-1	NULL
LTR	NULL
was	NULL
modified	NULL
.	NULL

Deletion	NULL
of	NULL
the	NULL
NF-KB	NULL
elements	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
significantly	NULL
inhibited	NULL
Tat-mediated	NULL
transactivation	NULL
in	NULL
T-cell	NULL
lines	NULL
,	NULL
as	NULL
well	NULL
as	NULL
in	NULL
a	NULL
monocyte	NULL
line	NULL
,	NULL
U937	NULL
.	NULL

Replacement	NULL
of	NULL
the	NULL
NF-KB	NULL
elements	NULL
in	NULL
the	NULL
HIV-1	NULL
LTR	NULL
by	NULL
a	NULL
DNA	NULL
fragment	NULL
derived	NULL
from	NULL
the	NULL
5	NULL
'	NULL
-flanking	NULL
region	NULL
of	NULL
IFN-stimulated	NULL
gene	NULL
15	NULL
(	NULL
ISG15	NULL
)	NULL
,	NULL
containing	NULL
the	NULL
IFN-stimulated	NULL
response	NULL
element	NULL
,	NULL
partially	NULL
restored	NULL
Tat-mediated	NULL
activation	NULL
of	NULL
LTR	NULL
in	NULL
T	NULL
cells	NULL
as	NULL
well	NULL
as	NULL
in	NULL
monocytes	NULL
.	NULL

Insertion	NULL
of	NULL
this	NULL
chimeric	NULL
promoter	NULL
(	NULL
ISG15	NULL
LTR	NULL
)	NULL
upstream	NULL
of	NULL
the	NULL
human	NULL
IFNA2	NULL
gene	NULL
directed	NULL
high	NULL
levels	NULL
of	NULL
IFN	NULL
synthesis	NULL
in	NULL
Tat-expressing	NULL
cells	NULL
,	NULL
while	NULL
this	NULL
promoter	NULL
was	NULL
not	NULL
responsive	NULL
to	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha-mediated	NULL
activation	NULL
.	NULL

ISG15-LTR-IFN	NULL
hybrid	NULL
gene	NULL
inserted	NULL
into	NULL
the	NULL
retrovirus	NULL
vector	NULL
was	NULL
transduced	NULL
into	NULL
Jurkat	NULL
and	NULL
U937	NULL
cells	NULL
.	NULL

Selected	NULL
transfected	NULL
clones	NULL
produced	NULL
low	NULL
levels	NULL
of	NULL
IFN	NULL
A	NULL
(	NULL
IFNA	NULL
)	NULL
constitutively	NULL
,	NULL
and	NULL
their	NULL
abilities	NULL
to	NULL
express	NULL
interleukin-2	NULL
and	NULL
interleukin-2	NULL
receptor	NULL
upon	NULL
stimulation	NULL
with	NULL
phytohemagglutinin	NULL
and	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
were	NULL
retained	NULL
.	NULL

Enhancement	NULL
of	NULL
IFNA	NULL
synthesis	NULL
observed	NULL
upon	NULL
HIV-1	NULL
infection	NULL
resulted	NULL
in	NULL
significant	NULL
inhibition	NULL
of	NULL
HIV-1	NULL
replication	NULL
for	NULL
a	NULL
period	NULL
of	NULL
at	NULL
least	NULL
30	NULL
days	NULL
.	NULL

Virus	NULL
isolated	NULL
from	NULL
IFNA-producing	NULL
cells	NULL
was	NULL
able	NULL
to	NULL
replicate	NULL
in	NULL
the	NULL
U937	NULL
cells	NULL
but	NULL
did	NULL
not	NULL
replicate	NULL
efficiently	NULL
in	NULL
U937	NULL
cells	NULL
transduced	NULL
with	NULL
the	NULL
IFNA	NULL
gene	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
targeting	NULL
IFN	NULL
synthesis	NULL
to	NULL
HIV-1-infected	NULL
cells	NULL
is	NULL
an	NULL
attainable	NULL
goal	NULL
and	NULL
that	NULL
autocrine	NULL
IFN	NULL
synthesis	NULL
results	NULL
in	NULL
a	NULL
long-lasting	NULL
and	NULL
permanent	NULL
suppression	NULL
of	NULL
HIV-1	NULL
replication	NULL
.	NULL

Human	NULL
interferon	NULL
A	NULL
(	NULL
IFNA	NULL
)	NULL
inhibits	NULL
replication	NULL
of	NULL
retrovi-ruses	NULL
,	NULL
including	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
,	NULL
an	NULL
etiological	NULL
agent	NULL
of	NULL
AIDS	NULL
(	NULL
11	NULL
,	NULL
17	NULL
,	NULL
21	NULL
,	NULL
26	NULL
,	NULL
41	NULL
,	NULL
55	NULL
)	NULL
.	NULL

Although	NULL
HIV-1	NULL
is	NULL
sensitive	NULL
to	NULL
IFN-mediated	NULL
inhibition	NULL
,	NULL
HIV-1	NULL
infection	NULL
does	NULL
not	NULL
induce	NULL
expression	NULL
of	NULL
IFNA	NULL
and	NULL
IFNB	NULL
genes	NULL
in	NULL
T	NULL
cells	NULL
or	NULL
monocytes	NULL
.	NULL

The	NULL
efficacy	NULL
of	NULL
IFNA	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
HIV-1	NULL
infection	NULL
and	NULL
AIDS-associated	NULL
Kaposi	NULL
's	NULL
sarcoma	NULL
has	NULL
been	NULL
demonstrated	NULL
in	NULL
clinical	NULL
trials	NULL
(	NULL
10	NULL
,	NULL
27	NULL
,	NULL
45	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
the	NULL
clinical	NULL
use	NULL
of	NULL
IFN	NULL
has	NULL
been	NULL
limited	NULL
by	NULL
frequent	NULL
side	NULL
effects	NULL
induced	NULL
by	NULL
the	NULL
administration	NULL
of	NULL
high	NULL
levels	NULL
of	NULL
exogenous	NULL
IFN	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
effective	NULL
inhibition	NULL
of	NULL
HIV-1	NULL
replication	NULL
in	NULL
vivo	NULL
may	NULL
require	NULL
continuous	NULL
administration	NULL
of	NULL
IFN	NULL
,	NULL
since	NULL
the	NULL
inhibitory	NULL
effect	NULL
in	NULL
vitro	NULL
was	NULL
reversed	NULL
upon	NULL
IFN	NULL
removal	NULL
(	NULL
22	NULL
,	NULL
42	NULL
,	NULL
62	NULL
)	NULL
.	NULL

Consequently	NULL
,	NULL
for	NULL
an	NULL
optimal	NULL
IFN	NULL
effect	NULL
and	NULL
effective	NULL
therapy	NULL
or	NULL
prophylaxis	NULL
of	NULL
AIDS	NULL
,	NULL
an	NULL
improved	NULL
method	NULL
of	NULL
IFN	NULL
delivery	NULL
is	NULL
desirable	NULL
.	NULL

Targeting	NULL
IFN	NULL
synthesis	NULL
to	NULL
a	NULL
focus	NULL
of	NULL
infection	NULL
by	NULL
a	NULL
transduced	NULL
IFN	NULL
gene	NULL
(	NULL
s	NULL
)	NULL
may	NULL
provide	NULL
the	NULL
most	NULL
effective	NULL
approach	NULL
.	NULL

In	NULL
our	NULL
previous	NULL
study	NULL
(	NULL
4	NULL
)	NULL
,	NULL
we	NULL
showed	NULL
that	NULL
HIV-1	NULL
replication	NULL
was	NULL
inhibited	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
containing	NULL
the	NULL
integrated	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
-IFNAZ	NULL
(	NULL
the	NULL
new	NULL
approved	NULL
no	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
The	NULL
Johns	NULL
Hopkins	NULL
University	NULL
Oncology	NULL
Center	NULL
,	NULL
418	NULL
N.	NULL
Bond	NULL
St.	NULL
,	NULL
Baltimore	NULL
,	NULL
MD	NULL
21231-1001	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
410	NULL
)	NULL
955-8871	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
410	NULL
)	NULL
955-0840	NULL
.	NULL

Electronic	NULL
mail	NULL
address	NULL
:	NULL
parowe	NULL
@	NULL
welchlink.welch	NULL
jhu.edu	NULL
.	NULL

¢	NULL
Present	NULL
address	NULL
:	NULL
Institute	NULL
of	NULL
Pharmacology	NULL
,	NULL
Department	NULL
of	NULL
Pharmacology	NULL
,	NULL
National	NULL
Yang-Ming	NULL
Medical	NULL
College	NULL
,	NULL
Shih-Pai	NULL
,	NULL
Taipei	NULL
11221	NULL
,	NULL
Taiwan	NULL
,	NULL
Republic	NULL
of	NULL
China	NULL
.	NULL

110	NULL
menclature	NULL
for	NULL
IFN	NULL
genes	NULL
is	NULL
used	NULL
throughout	NULL
this	NULL
article	NULL
[	NULL
10a	NULL
]	NULL
)	NULL
hybrid	NULL
gene	NULL
.	NULL

IFN	NULL
synthesis	NULL
was	NULL
increased	NULL
by	NULL
about	NULL
10	NULL
to	NULL
100	NULL
times	NULL
when	NULL
these	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
Tat-expressing	NULL
plasmid	NULL
.	NULL

However	NULL
,	NULL
virus-encoded	NULL
Tat	NULL
protein	NULL
is	NULL
not	NULL
the	NULL
only	NULL
factor	NULL
that	NULL
can	NULL
activate	NULL
transcription	NULL
of	NULL
HIV-1	NULL
LTR	NULL
and	NULL
mitogenic	NULL
stimuli	NULL
and	NULL
cytokines	NULL
,	NULL
or	NULL
infection	NULL
with	NULL
viruses	NULL
of	NULL
herpes	NULL
group	NULL
activates	NULL
HIV-1	NULL
LTR	NULL
in	NULL
a	NULL
Tat-independent	NULL
fashion	NULL
through	NULL
the	NULL
enhancer	NULL
elements	NULL
present	NULL
in	NULL
the	NULL
HIV-1	NULL
LTR	NULL
(	NULL
12	NULL
,	NULL
18	NULL
,	NULL
20	NULL
,	NULL
23	NULL
,	NULL
33	NULL
,	NULL
43	NULL
,	NULL
60	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
activation	NULL
through	NULL
these	NULL
enhancers	NULL
may	NULL
lead	NULL
to	NULL
nonspecific	NULL
activation	NULL
of	NULL
a	NULL
LTR-IFN	NULL
hybrid	NULL
gene	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
HIV-1	NULL
infection	NULL
.	NULL

Among	NULL
enhancer	NULL
elements	NULL
present	NULL
in	NULL
the	NULL
LTR	NULL
region	NULL
,	NULL
the	NULL
two	NULL
kB	NULL
motifs	NULL
were	NULL
shown	NULL
to	NULL
play	NULL
a	NULL
crucial	NULL
role	NULL
in	NULL
activating	NULL
expression	NULL
of	NULL
HIV-1	NULL
provirus	NULL
in	NULL
latently	NULL
infected	NULL
T	NULL
cells	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Transcriptional	NULL
activation	NULL
by	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
enhancer	NULL
is	NULL
mediated	NULL
by	NULL
binding	NULL
of	NULL
a	NULL
NF-kB	NULL
heterodimer	NULL
composed	NULL
of	NULL
50-kDa	NULL
(	NULL
p50	NULL
)	NULL
and	NULL
65-kDa	NULL
(	NULL
p65	NULL
)	NULL
subunits	NULL
(	NULL
2	NULL
,	NULL
25	NULL
,	NULL
59	NULL
)	NULL
.	NULL

In	NULL
most	NULL
of	NULL
the	NULL
cells	NULL
,	NULL
the	NULL
classic	NULL
NF-kB	NULL
(	NULL
p50-p65	NULL
)	NULL
is	NULL
present	NULL
in	NULL
an	NULL
inactive	NULL
form	NULL
in	NULL
cytoplasm	NULL
where	NULL
it	NULL
associates	NULL
with	NULL
the	NULL
inhibitory	NULL
protein	NULL
IxB	NULL
(	NULL
MAD3	NULL
)	NULL
(	NULL
1	NULL
,	NULL
63	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
NF-kB	NULL
,	NULL
which	NULL
involves	NULL
dissociation	NULL
of	NULL
p50/p65	NULL
heterodimer	NULL
from	NULL
IxB	NULL
and	NULL
subsequent	NULL
transport	NULL
to	NULL
the	NULL
nucleus	NULL
,	NULL
can	NULL
be	NULL
triggered	NULL
by	NULL
a	NULL
variety	NULL
of	NULL
extracellular	NULL
stimuli	NULL
,	NULL
including	NULL
cytokines	NULL
such	NULL
as	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
(	NULL
TNF-	NULL
«	NULL
)	NULL
and	NULL
interleukin-1	NULL
(	NULL
IL-1	NULL
)	NULL
(	NULL
38	NULL
)	NULL
,	NULL
double-stranded	NULL
RNA	NULL
(	NULL
29	NULL
)	NULL
,	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
infection	NULL
(	NULL
18	NULL
,	NULL
61	NULL
)	NULL
,	NULL
viral	NULL
transactivators	NULL
Tax	NULL
and	NULL
hepatitis	NULL
B	NULL
virus	NULL
X	NULL
protein	NULL
(	NULL
3	NULL
,	NULL
58	NULL
)	NULL
,	NULL
T-cell	NULL
mitogens	NULL
(	NULL
54	NULL
)	NULL
,	NULL
bacterial	NULL
lipopolysaccharide	NULL
(	NULL
54	NULL
)	NULL
,	NULL
UV	NULL
light	NULL
(	NULL
57	NULL
)	NULL
,	NULL
and	NULL
hydrogen	NULL
peroxide	NULL
(	NULL
53	NULL
)	NULL
.	NULL

It	NULL
is	NULL
well	NULL
established	NULL
that	NULL
IFNA	NULL
exerts	NULL
its	NULL
effects	NULL
by	NULL
binding	NULL
Vou	NULL
.	NULL

69	NULL
,	NULL
1995	NULL
to	NULL
a	NULL
specific	NULL
cell	NULL
surface	NULL
receptor	NULL
and	NULL
subsequently	NULL
enhancing	NULL
the	NULL
transcriptional	NULL
activities	NULL
of	NULL
a	NULL
specific	NULL
set	NULL
of	NULL
IFN-stimulated	NULL
genes	NULL
(	NULL
16	NULL
,	NULL
28	NULL
)	NULL
.	NULL

The	NULL
coordinate	NULL
transcriptional	NULL
control	NULL
of	NULL
these	NULL
genes	NULL
depends	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
consensus	NULL
enhancer	NULL
sequence	NULL
,	NULL
the	NULL
IFN-stimulated	NULL
response	NULL
element	NULL
(	NULL
ISRE	NULL
)	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Since	NULL
our	NULL
goal	NULL
has	NULL
been	NULL
to	NULL
obtain	NULL
prolonged	NULL
high	NULL
concentrations	NULL
of	NULL
IFNA	NULL
at	NULL
the	NULL
site	NULL
of	NULL
infection	NULL
,	NULL
we	NULL
wished	NULL
to	NULL
determine	NULL
whether	NULL
IFN	NULL
production	NULL
from	NULL
a	NULL
transduced	NULL
gene	NULL
could	NULL
be	NULL
augmented	NULL
through	NULL
a	NULL
putative	NULL
feedback	NULL
mechanism	NULL
.	NULL

Using	NULL
a	NULL
HIV-1	NULL
LTR-chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
plasmid	NULL
that	NULL
had	NULL
a	NULL
xB	NULL
enhancer	NULL
deleted	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
responsiveness	NULL
of	NULL
a	NULL
plasmid	NULL
with	NULL
this	NULL
xB-deleted	NULL
LTR	NULL
to	NULL
Tat	NULL
in	NULL
various	NULL
cell	NULL
types	NULL
that	NULL
can	NULL
be	NULL
infected	NULL
with	NULL
HIV-1	NULL
.	NULL

We	NULL
also	NULL
tested	NULL
the	NULL
possibility	NULL
of	NULL
maintaining	NULL
high	NULL
levels	NULL
of	NULL
Tat-mediated	NULL
IFN	NULL
expression	NULL
by	NULL
substituting	NULL
the	NULL
two	NULL
kB	NULL
motifs	NULL
in	NULL
HIV-1	NULL
LTR	NULL
with	NULL
either	NULL
ISRE	NULL
or	NULL
a	NULL
segment	NULL
of	NULL
the	NULL
promoter	NULL
region	NULL
of	NULL
the	NULL
ISG15	NULL
gene	NULL
(	NULL
IFN-stimulated	NULL
gene	NULL
15	NULL
)	NULL
containing	NULL
an	NULL
ISRE	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
deletion	NULL
of	NULL
the	NULL
two	NULL
NF-kB	NULL
enhancer	NULL
elements	NULL
significantly	NULL
decreased	NULL
the	NULL
efficiency	NULL
of	NULL
Tat-mediated	NULL
transactivation	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
in	NULL
both	NULL
T	NULL
cells	NULL
and	NULL
monocytes	NULL
.	NULL

Replacement	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
enhancers	NULL
by	NULL
the	NULL
promoter	NULL
region	NULL
of	NULL
the	NULL
ISG15	NULL
gene	NULL
increased	NULL
Tat-mediated	NULL
transactivation	NULL
in	NULL
both	NULL
types	NULL
of	NULL
cells	NULL
,	NULL
while	NULL
this	NULL
promoter	NULL
was	NULL
not	NULL
activated	NULL
by	NULL
TNF-	NULL
«	NULL
.	NULL

HIV-1	NULL
infection	NULL
of	NULL
T	NULL
cells	NULL
and	NULL
U937	NULL
cells	NULL
containing	NULL
the	NULL
transactivable	NULL
IFNA	NULL
gene	NULL
leads	NULL
to	NULL
stimulation	NULL
of	NULL
IFNA	NULL
synthesis	NULL
and	NULL
long-lasting	NULL
inhibition	NULL
of	NULL
HIV-1	NULL
replication	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
cultures	NULL
.	NULL

Hela	NULL
,	NULL
Vero	NULL
,	NULL
and	NULL
bovine	NULL
embryonic	NULL
trachea	NULL
cells	NULL
(	NULL
ATCC	NULL
CCL-44	NULL
)	NULL
were	NULL
maintained	NULL
in	NULL
Dulbecco	NULL
modified	NULL
Eagle	NULL
medium	NULL
(	NULL
Life	NULL
Technol-ogies	NULL
,	NULL
Inc.	NULL
Grand	NULL
Island	NULL
,	NULL
N.Y.	NULL
)	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
,	NULL
2	NULL
mM	NULL
glutamine	NULL
,	NULL
and	NULL
50	NULL
ug	NULL
of	NULL
gentamicin	NULL
per	NULL
ml	NULL
.	NULL

A3.01	NULL
,	NULL
CEM-174	NULL
,	NULL
Jurkat	NULL
,	NULL
and	NULL
U937	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
at	NULL
a	NULL
density	NULL
of	NULL
3	NULL
X	NULL
10°	NULL
cells	NULL
per	NULL
ml	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
55	NULL
)	NULL
.	NULL

Plasmid	NULL
constructions	NULL
.	NULL

Cloning	NULL
of	NULL
various	NULL
restriction	NULL
fragments	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
by	NULL
Sambrook	NULL
et	NULL
al	NULL
.	NULL

(	NULL
51	NULL
)	NULL
.	NULL

The	NULL
ISG15-CAT	NULL
hybrid	NULL
plasmid	NULL
was	NULL
constructed	NULL
by	NULL
inserting	NULL
the	NULL
EcoRI-BemHI	NULL
fragment	NULL
,	NULL
which	NULL
contains	NULL
-366	NULL
to	NULL
+44	NULL
of	NULL
the	NULL
ISG15	NULL
promoter	NULL
from	NULL
plasmid	NULL
NcoISG15-E1B	NULL
(	NULL
46	NULL
)	NULL
,	NULL
between	NULL
the	NULL
Psfl	NULL
and	NULL
BamHI	NULL
sites	NULL
of	NULL
pBLCAT-3	NULL
(	NULL
32	NULL
)	NULL
.	NULL

The	NULL
(	NULL
ISRE	NULL
)	NULL
,	NULL
(	NULL
-119	NULL
)	NULL
HIV-1	NULL
LTR-CAT	NULL
plasmid	NULL
was	NULL
constructed	NULL
by	NULL
subcloning	NULL
an	NULL
EcoRI	NULL
fragment	NULL
,	NULL
containing	NULL
three	NULL
copies	NULL
of	NULL
ISRE	NULL
of	NULL
ISG15	NULL
from	NULL
ISG15-TK-3	NULL
plasmid	NULL
(	NULL
47	NULL
)	NULL
,	NULL
into	NULL
the	NULL
Xhol	NULL
site	NULL
of	NULL
(	NULL
-119	NULL
)	NULL
HIV-1	NULL
LTR-CAT	NULL
(	NULL
48	NULL
)	NULL
.	NULL

ISG15	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR-CAT	NULL
plasmid	NULL
was	NULL
constructed	NULL
by	NULL
subcloning	NULL
a	NULL
HindIII-Ddel	NULL
fragment	NULL
containing	NULL
-366	NULL
to	NULL
-36	NULL
of	NULL
the	NULL
ISG15	NULL
promoter	NULL
between	NULL
the	NULL
HindIII	NULL
and	NULL
Psfl	NULL
sites	NULL
of	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR-CAT	NULL
(	NULL
56	NULL
)	NULL
.	NULL

Retrovirus	NULL
vectors	NULL
containing	NULL
the	NULL
modified	NULL
HIV-1	NULL
LTR-IFNA2	NULL
hybrid	NULL
gene	NULL
were	NULL
constructed	NULL
by	NULL
cloning	NULL
the	NULL
IFNAZ	NULL
gene	NULL
(	NULL
4	NULL
)	NULL
between	NULL
the	NULL
HindIII	NULL
and	NULL
BamHI	NULL
sites	NULL
of	NULL
pBluescript	NULL
SK	NULL
plasmid	NULL
(	NULL
Stratagene	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

The	NULL
HindIII-KpnI	NULL
fragments	NULL
containing	NULL
either	NULL
the	NULL
ISG15	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
or	NULL
HIV-1	NULL
LTR	NULL
(	NULL
-83	NULL
to	NULL
+80	NULL
)	NULL
were	NULL
then	NULL
subcloned	NULL
into	NULL
the	NULL
ClaI	NULL
site	NULL
of	NULL
this	NULL
plasmid	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
Xhol-Xbel	NULL
fragment	NULL
containing	NULL
the	NULL
modified	NULL
HIV-1	NULL
LTR-IFNA2	NULL
hybrid	NULL
gene	NULL
from	NULL
the	NULL
plasmid	NULL
described	NULL
above	NULL
were	NULL
subcloned	NULL
into	NULL
the	NULL
BamHI	NULL
site	NULL
of	NULL
retrovirus	NULL
vector	NULL
pLJenh~	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Transfection	NULL
and	NULL
induction	NULL
of	NULL
expression	NULL
in	NULL
a	NULL
transient	NULL
transfection	NULL
assay	NULL
.	NULL

HeLa	NULL
and	NULL
Vero	NULL
cells	NULL
were	NULL
transfected	NULL
by	NULL
calcium	NULL
phosphate	NULL
coprecipitation	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
cells	NULL
were	NULL
seeded	NULL
at	NULL
a	NULL
density	NULL
of	NULL
5	NULL
X	NULL
10°	NULL
cells	NULL
per	NULL
60-mm-diameter	NULL
plate	NULL
,	NULL
and	NULL
24	NULL
h	NULL
later	NULL
,	NULL
2	NULL
mg	NULL
of	NULL
reporter	NULL
CAT	NULL
or	NULL
IFNA	NULL
plasmid	NULL
and	NULL
1	NULL
pg	NULL
of	NULL
Tat-encoding	NULL
plasmid	NULL
were	NULL
added	NULL
as	NULL
calcium	NULL
phosphate	NULL
precipitate	NULL
.	NULL

After	NULL
5	NULL
h	NULL
of	NULL
incubation	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
15	NULL
%	NULL
glycerol	NULL
for	NULL
1	NULL
min	NULL
,	NULL
washed	NULL
twice	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
,	NULL
and	NULL
incubated	NULL
for	NULL
an	NULL
additional	NULL
48	NULL
h.	NULL
CAT	NULL
extracts	NULL
were	NULL
then	NULL
prepared	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
19	NULL
)	NULL
.	NULL

The	NULL
A3.01	NULL
,	NULL
CEM-174	NULL
,	NULL
Jurkat	NULL
,	NULL
and	NULL
U937	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
similar	NULL
amounts	NULL
of	NULL
plasmids	NULL
by	NULL
DEAE-dextran	NULL
coprecipitation	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
5	NULL
X	NULL
10°	NULL
cells	NULL
were	NULL
washed	NULL
and	NULL
incubated	NULL
with	NULL
plasmid	NULL
DNA	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
DEAE-dextran	NULL
(	NULL
100	NULL
pg/ml	NULL
;	NULL
Pharmacia	NULL
,	NULL
Piscataway	NULL
,	NULL
N.J.	NULL
)	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
for	NULL
10	NULL
min	NULL
at	NULL
37°C	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
washed	NULL
,	NULL
refed	NULL
with	NULL
medium	NULL
,	NULL
and	NULL
incubated	NULL
for	NULL
48	NULL
h	NULL
before	NULL
harvest	NULL
for	NULL
the	NULL
CAT	NULL
assay	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
effect	NULL
of	NULL
IFNA	NULL
,	NULL
transfected	NULL
cells	NULL
were	NULL
divided	NULL
into	NULL
duplicate	NULL
plates	NULL
after	NULL
DEAE-dextran	NULL
was	NULL
washed	NULL
off	NULL
,	NULL
and	NULL
16	NULL
h	NULL
later	NULL
,	NULL
human	NULL
recombinant	NULL
IFNA	NULL
(	NULL
Hoffman-LaRoche	NULL
Inc.	NULL
,	NULL
Nutley	NULL
,	NULL
N.J.	NULL
)	NULL
was	NULL
added	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
1,000	NULL
U/ml	NULL
to	NULL
one	NULL
of	NULL
the	NULL
plates	NULL
.	NULL

Cells	NULL
were	NULL
processed	NULL
for	NULL
the	NULL
CAT	NULL
assay	NULL
24	NULL
h	NULL
after	NULL
the	NULL
addition	NULL
of	NULL
IFNA	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
effect	NULL
of	NULL
IFNA	NULL
on	NULL
Tat-mediated	NULL
transactivation	NULL
,	NULL
CEM-174	NULL
or	NULL
U937	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
reporter	NULL
CAT	NULL
plasmids	NULL
and	NULL
pMMextefIII	NULL
(	NULL
1	NULL
g	NULL
)	NULL
.	NULL

The	NULL
reproducibility	NULL
of	NULL
the	NULL
transfection	NULL
experi-	NULL
SELECTIVE	NULL
EXPRESSION	NULL
OF	NULL
A	NULL
TRANSDUCED	NULL
IFN	NULL
GENE	NULL
111	NULL
ments	NULL
was	NULL
ascertained	NULL
by	NULL
repeating	NULL
each	NULL
experiment	NULL
at	NULL
least	NULL
twice	NULL
.	NULL

Comparable	NULL
results	NULL
were	NULL
obtained	NULL
in	NULL
all	NULL
instances	NULL
.	NULL

Permanently	NULL
transfected	NULL
cell	NULL
lines	NULL
were	NULL
established	NULL
by	NULL
electroporation	NULL
of	NULL
the	NULL
retrovirus	NULL
vectors	NULL
containing	NULL
hybrid	NULL
IFNA	NULL
genes	NULL
and	NULL
selection	NULL
of	NULL
the	NULL
transduced	NULL
cells	NULL
by	NULL
growth	NULL
in	NULL
G418	NULL
.	NULL

The	NULL
selected	NULL
cells	NULL
were	NULL
cloned	NULL
by	NULL
limiting	NULL
dilutions	NULL
and	NULL
allowed	NULL
to	NULL
grow	NULL
into	NULL
the	NULL
cultures	NULL
.	NULL

RNA	NULL
isolation	NULL
and	NULL
analysis	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
prepared	NULL
from	NULL
Hela	NULL
cells	NULL
,	NULL
collected	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
and	NULL
U937	NULL
cells	NULL
,	NULL
14	NULL
days	NULL
after	NULL
infection	NULL
with	NULL
HIV-1	NULL
,	NULL
by	NULL
the	NULL
guanidinium	NULL
thiocyanate	NULL
method	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Northern	NULL
(	NULL
RNA	NULL
)	NULL
blot	NULL
hybridization	NULL
was	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
44	NULL
)	NULL
,	NULL
using	NULL
a	NULL
CAT	NULL
riboprobe	NULL
.	NULL

To	NULL
examine	NULL
IFN-induced	NULL
expression	NULL
of	NULL
ISG15	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
IFNA	NULL
(	NULL
1,000	NULL
U/m	NULL
!	NULL
)	NULL

for	NULL
3	NULL
h	NULL
,	NULL
and	NULL
total	NULL
RNA	NULL
was	NULL
isolated	NULL
by	NULL
the	NULL
acid	NULL
phenol-guanidinium	NULL
thiocyanate	NULL
procedure	NULL
(	NULL
9	NULL
)	NULL
and	NULL
analyzed	NULL
by	NULL
Northern	NULL
blot	NULL
hybridization	NULL
with	NULL
an	NULL
ISG15	NULL
riboprobe	NULL
.	NULL

IFN	NULL
assays	NULL
.	NULL

The	NULL
media	NULL
were	NULL
collected	NULL
from	NULL
Vero	NULL
,	NULL
U937	NULL
,	NULL
or	NULL
Jurkat	NULL
cells	NULL
48	NULL
h	NULL
after	NULL
transfection	NULL
.	NULL

The	NULL
media	NULL
from	NULL
the	NULL
permanently	NULL
transfected	NULL
Jurkat	NULL
and	NULL
U937	NULL
cells	NULL
before	NULL
or	NULL
after	NULL
HIV-1	NULL
infection	NULL
were	NULL
collected	NULL
as	NULL
indicated	NULL
.	NULL

Biologically	NULL
active	NULL
IFN	NULL
was	NULL
assayed	NULL
in	NULL
duplicate	NULL
by	NULL
inhibition	NULL
of	NULL
the	NULL
cytopathic	NULL
effect	NULL
of	NULL
vesicular	NULL
stomatitis	NULL
virus	NULL
on	NULL
bovine	NULL
embryonic	NULL
trachea	NULL
cells	NULL
(	NULL
15	NULL
)	NULL
.	NULL

The	NULL
level	NULL
of	NULL
IFN	NULL
antiviral	NULL
activity	NULL
in	NULL
cach	NULL
sample	NULL
was	NULL
quantitated	NULL
by	NULL
comparison	NULL
with	NULL
standards	NULL
of	NULL
human	NULL
recombinant	NULL
IFNA2	NULL
(	NULL
Hoffman-LaRoche	NULL
)	NULL
.	NULL

HIV-1	NULL
infection	NULL
.	NULL

The	NULL
HIV-1	NULL
pLN4-3	NULL
strain	NULL
obtained	NULL
from	NULL
M.	NULL
Martin	NULL
was	NULL
used	NULL
in	NULL
all	NULL
experiments	NULL
.	NULL

Virus	NULL
stock	NULL
was	NULL
obtained	NULL
from	NULL
activated	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PMBC	NULL
)	NULL
and	NULL
titrated	NULL
on	NULL
C8166	NULL
cells	NULL
,	NULL
and	NULL
unless	NULL
otherwise	NULL
stated	NULL
,	NULL
all	NULL
infections	NULL
were	NULL
done	NULL
with	NULL
a	NULL
multiplicity	NULL
of	NULL
infection	NULL
(	NULL
MOI	NULL
)	NULL
of	NULL
0.01	NULL
.	NULL

Jurkat	NULL
and	NULL
U937	NULL
cells	NULL
and	NULL
the	NULL
permanently	NULL
transfected	NULL
clones	NULL
were	NULL
plated	NULL
at	NULL
10°	NULL
cells	NULL
per	NULL
ml	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
and	NULL
infected	NULL
with	NULL
the	NULL
pNL4-3	NULL
strain	NULL
of	NULL
HIV-1	NULL
.	NULL

Every	NULL
third	NULL
day	NULL
,	NULL
50	NULL
%	NULL
of	NULL
culture	NULL
medium	NULL
was	NULL
removed	NULL
and	NULL
replaced	NULL
with	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
fresh	NULL
medium	NULL
.	NULL

Virus	NULL
in	NULL
the	NULL
collected	NULL
medium	NULL
was	NULL
analyzed	NULL
by	NULL
a	NULL
reverse	NULL
transcriptase	NULL
(	NULL
RT	NULL
)	NULL
assay	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
55	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
IL-2	NULL
and	NULL
IL-2R	NULL
gene	NULL
expression	NULL
.	NULL

Jurkat	NULL
cells	NULL
or	NULL
JISGA3A	NULL
clone	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
phytohemagglutinin	NULL
(	NULL
PHA	NULL
)	NULL
(	NULL
5	NULL
ug/ml	NULL
)	NULL
and	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
(	NULL
50	NULL
pg/ml	NULL
)	NULL
for	NULL
16	NULL
h	NULL
;	NULL
cells	NULL
were	NULL
then	NULL
washed	NULL
and	NULL
harvested	NULL
,	NULL
and	NULL
total	NULL
RNA	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
was	NULL
analyzed	NULL
by	NULL
Northern	NULL
blot	NULL
hybridization	NULL
with	NULL
IL-2	NULL
DNA	NULL
probe	NULL
(	NULL
pCDHuIL-2	NULL
)	NULL
and	NULL
IL-2	NULL
receptor	NULL
B	NULL
(	NULL
IL-2RB	NULL
)	NULL
-specific	NULL
riboprobes	NULL
.	NULL

RESULTS	NULL
NF-B-binding	NULL
sites	NULL
are	NULL
required	NULL
for	NULL
efficient	NULL
Tat	NULL
activation	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
and	NULL
monocytes	NULL
.	NULL

Several	NULL
earlier	NULL
studies	NULL
had	NULL
addressed	NULL
the	NULL
question	NULL
of	NULL
the	NULL
importance	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
elements	NULL
of	NULL
HIV-1	NULL
LTR	NULL
in	NULL
Tat-mediated	NULL
transactivation	NULL
with	NULL
somewhat	NULL
different	NULL
results	NULL
(	NULL
36	NULL
,	NULL
56	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
initially	NULL
tested	NULL
whether	NULL
the	NULL
NF-	NULL
«	NULL
xB-binding	NULL
sites	NULL
could	NULL
be	NULL
deleted	NULL
without	NULL
affecting	NULL
the	NULL
magnitude	NULL
of	NULL
Tat	NULL
activation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
.	NULL

Several	NULL
human	NULL
T-cell	NULL
lines	NULL
(	NULL
¥A3.01	NULL
,	NULL
CEM-174	NULL
,	NULL
and	NULL
Jurkat	NULL
)	NULL
and	NULL
one	NULL
promonocytic	NULL
cell	NULL
line	NULL
(	NULL
U937	NULL
)	NULL
were	NULL
chosen	NULL
as	NULL
hosts	NULL
,	NULL
and	NULL
expression	NULL
of	NULL
the	NULL
plasmids	NULL
containing	NULL
HIV-1	NULL
LTR	NULL
with	NULL
(	NULL
-119	NULL
)	NULL
or	NULL
without	NULL
(	NULL
-83	NULL
)	NULL
(	NULL
dkB	NULL
HIV-1	NULL
LTR	NULL
)	NULL
NF-	NULL
«	NULL
B-binding	NULL
sites	NULL
was	NULL
examined	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
a	NULL
Tat-expressing	NULL
plasmid	NULL
(	NULL
plMex-tatIII	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
expression	NULL
of	NULL
a	NULL
xB-deleted	NULL
mutant	NULL
[	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
]	NULL
was	NULL
not	NULL
efficiently	NULL
activated	NULL
by	NULL
Tat	NULL
in	NULL
any	NULL
of	NULL
the	NULL
three	NULL
T-cell	NULL
lines	NULL
tested	NULL
(	NULL
lanes	NULL
4	NULL
,	NULL
8	NULL
,	NULL
and	NULL
12	NULL
)	NULL
when	NULL
measured	NULL
under	NULL
conditions	NULL
of	NULL
linear	NULL
response	NULL
.	NULL

A	NULL
low	NULL
degree	NULL
of	NULL
activation	NULL
of	NULL
the	NULL
«	NULL
B-deleted	NULL
mutant	NULL
[	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
]	NULL
could	NULL
be	NULL
achieved	NULL
when	NULL
10-fold-higher	NULL
levels	NULL
of	NULL
Tat-expressing	NULL
plasmid	NULL
were	NULL
used	NULL
for	NULL
transactivation	NULL
;	NULL
however	NULL
,	NULL
these	NULL
conditions	NULL
were	NULL
far	NULL
out	NULL
of	NULL
the	NULL
linear	NULL
response	NULL
and	NULL
therefore	NULL
,	NULL
not	NULL
meaningful	NULL
for	NULL
our	NULL
comparative	NULL
analyses	NULL
.	NULL

Tat-mediated	NULL
activation	NULL
of	NULL
the	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
was	NULL
observed	NULL
in	NULL
U937	NULL
cells	NULL
(	NULL
lane	NULL
16	NULL
)	NULL
,	NULL
but	NULL
the	NULL
levels	NULL
of	NULL
CAT	NULL
activity	NULL
were	NULL
at	NULL
least	NULL
fivefold	NULL
lower	NULL
than	NULL
those	NULL
expressed	NULL
by	NULL
a	NULL
plasmid	NULL
containing	NULL
the	NULL
intact	NULL
NF-	NULL
«	NULL
B-binding	NULL
sites	NULL
(	NULL
lane	NULL
14	NULL
)	NULL
.	NULL

Since	NULL
earlier	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
NF-kB-binding	NULL
sites	NULL
are	NULL
not	NULL
required	NULL
for	NULL
Tat	NULL
activation	NULL
in	NULL
either	NULL
Jurkat	NULL
or	NULL
HeLa	NULL
cells	NULL
(	NULL
56	NULL
)	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
reasons	NULL
for	NULL
this	NULL
discrepancy	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
T	NULL
cells	NULL
and	NULL
monocytes	NULL
,	NULL
we	NULL
observed	NULL
significant	NULL
Tat	NULL
activation	NULL
from	NULL
the	NULL
<	NULL
B-deleted	NULL
mutant	NULL
in	NULL
HeLa	NULL
cells	NULL
(	NULL
lane	NULL
20	NULL
)	NULL
.	NULL

However	NULL
,	NULL
when	NULL
analyzed	NULL
under	NULL
conditions	NULL
of	NULL
a	NULL
linear	NULL
response	NULL
,	NULL
a	NULL
dramatic	NULL
difference	NULL
in	NULL
Tat	NULL
activation	NULL
of	NULL
(	NULL
-119	NULL
)	NULL
HIV-1	NULL
LTR	NULL
and	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
was	NULL
found	NULL
,	NULL
even	NULL
in	NULL
HeLa	NULL
cells	NULL
(	NULL
lanes	NULL
21	NULL
and	NULL
22	NULL
)	NULL
.	NULL

These	NULL
data	NULL
confirm	NULL
the	NULL
previous	NULL
112	NULL
SU	NULL
ET	NULL
AL	NULL
.	NULL

J.	NULL
ViroL	NULL
.	NULL

NFkB	NULL
SP1	NULL
(	NULL
-*19	NULL
)	NULL
HIV	NULL
LTR	NULL
TATA	NULL
|	NULL
TAA	NULL
CAT	NULL
[	NULL
-89	NULL
;	NULL
HIV	NULL
LTR	NULL
TATA	NULL
|	NULL
TAR	NULL
CAT	NULL
Cell	NULL
type	NULL
A3.01	NULL
CEM-174	NULL
Jurkat	NULL
Reporter	NULL
-119	NULL
+83	NULL
-119	NULL
-83	NULL
119	NULL
-83	NULL
Tat	NULL
-	NULL
I	NULL
+	NULL
I	NULL
+	NULL
-	NULL
I	NULL
+	NULL
-	NULL
I	NULL
+	NULL
I	NULL
+	NULL
I	NULL
+	NULL
T	NULL
©	NULL
#	NULL
%	NULL
#	NULL
#	NULL
:	NULL
[	NULL
2	NULL
[	NULL
sa	NULL
[	NULL
+	NULL
[	NULL
s	NULL
[	NULL
s	NULL
[	NULL
T7	NULL
[	NULL
«	NULL
]	NULL
(	NULL
+	NULL
Tn	NULL
[	NULL
v	NULL
Tr	NULL
]	NULL
U937	NULL
Hela	NULL
118	NULL
-83	NULL
119	NULL
+83	NULL
~119|	NULL
-83	NULL
_288	NULL
-	NULL
[	NULL
+	NULL
[	NULL
-	NULL
[	NULL
++	NULL
T+	NULL
I+	NULL
]	NULL
+	NULL
o	NULL
*	NULL
0	NULL
T6	NULL
%	NULL
.	NULL

@	NULL
-18S	NULL
e	NULL
o	NULL
e	NULL
o	NULL
0	NULL
0	NULL
=	NULL
00	NULL
)	NULL
0	NULL
0	NULL
ts	NULL
|	NULL
a4	NULL
|	NULL
as	NULL
16I17I15I19I20	NULL
21L22	NULL
1	NULL
2	NULL
3	NULL
4	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Efficient	NULL
activation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
by	NULL
Tat	NULL
requires	NULL
the	NULL
presence	NULL
of	NULL
«	NULL
B	NULL
motifs	NULL
.	NULL

(	NULL
-119	NULL
)	NULL
HIV-1	NULL
LTR	NULL
and	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR-CAT	NULL
(	NULL
shown	NULL
schematically	NULL
at	NULL
the	NULL
top	NULL
of	NULL
the	NULL
figure	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
(	NULL
+	NULL
)	NULL
or	NULL
without	NULL
(	NULL
-	NULL
)	NULL
pMextafIII	NULL
(	NULL
Tat	NULL
)	NULL
into	NULL
T	NULL
cells	NULL
and	NULL
monocyte	NULL
lines	NULL
.	NULL

The	NULL
CAT	NULL
assay	NULL
was	NULL
performed	NULL
48	NULL
h	NULL
after	NULL
transfection	NULL
by	NULL
using	NULL
40	NULL
g	NULL
of	NULL
cell	NULL
extract	NULL
in	NULL
a	NULL
1-h	NULL
reaction	NULL
at	NULL
37°C	NULL
,	NULL
except	NULL
for	NULL
the	NULL
assays	NULL
shown	NULL
in	NULL
lanes	NULL
21	NULL
and	NULL
22	NULL
in	NULL
which	NULL
20	NULL
pg	NULL
of	NULL
cytosol	NULL
was	NULL
used	NULL
and	NULL
incubation	NULL
was	NULL
for	NULL
15	NULL
min	NULL
.	NULL

In	NULL
A3.01	NULL
cells	NULL
transfected	NULL
with	NULL
(	NULL
-119	NULL
)	NULL
HIV-1	NULL
LTR-CAT	NULL
(	NULL
-119	NULL
)	NULL
,	NULL
the	NULL
conversion	NULL
was	NULL
in	NULL
the	NULL
range	NULL
of	NULL
1.5	NULL
to	NULL
2.4	NULL
%	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Tat	NULL
and	NULL
65	NULL
to	NULL
75	NULL
%	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Tat	NULL
,	NULL
while	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR-CAT	NULL
(	NULL
-83	NULL
)	NULL
,	NULL
the	NULL
values	NULL
for	NULL
conversion	NULL
were	NULL
1.2	NULL
and	NULL
2.1	NULL
%	NULL
,	NULL
respectively	NULL
;	NULL
the	NULL
exception	NULL
was	NULL
U937	NULL
cells	NULL
in	NULL
which	NULL
the	NULL
conversion	NULL
of	NULL
this	NULL
plasmid	NULL
was	NULL
about	NULL
6	NULL
%	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Tat	NULL
.	NULL

In	NULL
the	NULL
gel	NULL
in	NULL
the	NULL
lower	NULL
right-hand	NULL
of	NULL
the	NULL
figure	NULL
,	NULL
total	NULL
RNA	NULL
(	NULL
15	NULL
pg	NULL
)	NULL
prepared	NULL
from	NULL
HeLa	NULL
cells	NULL
at	NULL
24	NULL
h	NULL
posttransfection	NULL
was	NULL
analyzed	NULL
by	NULL
Northern	NULL
blot	NULL
hybridization	NULL
with	NULL
the	NULL
CAT	NULL
antisense	NULL
riboprobes	NULL
.	NULL

observation	NULL
that	NULL
in	NULL
HeLa	NULL
cells	NULL
,	NULL
the	NULL
NF-kB	NULL
sites	NULL
are	NULL
not	NULL
required	NULL
for	NULL
transactivation	NULL
.	NULL

These	NULL
data	NULL
also	NULL
clearly	NULL
show	NULL
that	NULL
the	NULL
magnitude	NULL
of	NULL
Tat	NULL
transactivation	NULL
is	NULL
lower	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
NF-	NULL
«	NULL
B-binding	NULL
factors	NULL
and	NULL
that	NULL
the	NULL
effect	NULL
of	NULL
Tat	NULL
and	NULL
NF-kB	NULL
is	NULL
more	NULL
than	NULL
additive	NULL
.	NULL

To	NULL
confirm	NULL
that	NULL
CAT	NULL
activity	NULL
is	NULL
a	NULL
valid	NULL
measure	NULL
of	NULL
steady-state	NULL
CAT	NULL
mRNA	NULL
levels	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
levels	NULL
of	NULL
CAT	NULL
RNA	NULL
in	NULL
HeLa	NULL
cells	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
the	NULL
gel	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
the	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR-CAT	NULL
plasmid	NULL
was	NULL
transactivated	NULL
by	NULL
Tat	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
but	NULL
the	NULL
relative	NULL
levels	NULL
of	NULL
CAT	NULL
mRNA	NULL
were	NULL
much	NULL
lower	NULL
than	NULL
those	NULL
encoded	NULL
by	NULL
the	NULL
wild-type	NULL
HIV-1	NULL
LTR-CAT	NULL
plasmid	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

To	NULL
rule	NULL
out	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
observed	NULL
difference	NULL
in	NULL
CAT	NULL
activity	NULL
might	NULL
have	NULL
resulted	NULL
from	NULL
different	NULL
transfection	NULL
efficiencies	NULL
,	NULL
the	NULL
amounts	NULL
of	NULL
plasmid	NULL
in	NULL
the	NULL
cytosol	NULL
from	NULL
the	NULL
transfected	NULL
cells	NULL
were	NULL
determined	NULL
by	NULL
dot	NULL
blot	NULL
analysis	NULL
(	NULL
34	NULL
)	NULL
.	NULL

No	NULL
significant	NULL
differences	NULL
in	NULL
the	NULL
amount	NULL
of	NULL
plasmid	NULL
DNA	NULL
were	NULL
found	NULL
between	NULL
each	NULL
transfection	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
NF-kB-binding	NULL
sites	NULL
of	NULL
HIV-1	NULL
LTR	NULL
may	NULL
not	NULL
be	NULL
essential	NULL
for	NULL
Tat	NULL
activation	NULL
in	NULL
HeLa	NULL
or	NULL
U937	NULL
cells	NULL
,	NULL
but	NULL
these	NULL
cis	NULL
elements	NULL
appear	NULL
to	NULL
be	NULL
much	NULL
more	NULL
important	NULL
for	NULL
Tat	NULL
activation	NULL
in	NULL
the	NULL
human	NULL
T-cell	NULL
lines	NULL
we	NULL
tested	NULL
.	NULL

It	NULL
should	NULL
be	NULL
pointed	NULL
out	NULL
that	NULL
although	NULL
others	NULL
(	NULL
49	NULL
)	NULL
have	NULL
shown	NULL
that	NULL
HIV-1	NULL
provirus	NULL
which	NULL
had	NULL
NF-	NULL
«	NULL
B	NULL
sites	NULL
deleted	NULL
was	NULL
able	NULL
to	NULL
replicate	NULL
in	NULL
PBMC	NULL
,	NULL
its	NULL
replication	NULL
rate	NULL
was	NULL
much	NULL
slower	NULL
than	NULL
that	NULL
of	NULL
the	NULL
wild	NULL
type	NULL
.	NULL

Expression	NULL
of	NULL
ISG15	NULL
in	NULL
human	NULL
T	NULL
and	NULL
promonocytic	NULL
cells	NULL
can	NULL
be	NULL
induced	NULL
by	NULL
IFNA	NULL
.	NULL

To	NULL
compensate	NULL
for	NULL
the	NULL
decrease	NULL
of	NULL
promoter	NULL
activity	NULL
of	NULL
HIV-1	NULL
LTR	NULL
caused	NULL
by	NULL
removal	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B-binding	NULL
sites	NULL
,	NULL
we	NULL
examined	NULL
whether	NULL
insertion	NULL
of	NULL
a	NULL
well-defined	NULL
IFN	NULL
response	NULL
element	NULL
(	NULL
ISRE	NULL
)	NULL
from	NULL
the	NULL
ISG15	NULL
promoter	NULL
region	NULL
(	NULL
46	NULL
)	NULL
,	NULL
upstream	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
,	NULL
could	NULL
enhance	NULL
the	NULL
promoter	NULL
activity	NULL
of	NULL
HIV-1	NULL
LTR	NULL
.	NULL

Since	NULL
most	NULL
of	NULL
the	NULL
early	NULL
studies	NULL
showed	NULL
IFNA-mediated	NULL
induction	NULL
of	NULL
ISG15	NULL
gene	NULL
in	NULL
HeLa	NULL
or	NULL
other	NULL
human	NULL
fibroblast	NULL
cell	NULL
lines	NULL
(	NULL
16	NULL
,	NULL
31	NULL
,	NULL
46	NULL
)	NULL
,	NULL
we	NULL
examined	NULL
whether	NULL
the	NULL
ISG15	NULL
gene	NULL
can	NULL
also	NULL
be	NULL
induced	NULL
in	NULL
IFNA-treated	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
A3.01	NULL
,	NULL
CEM-174	NULL
,	NULL
and	NULL
Jurkat	NULL
)	NULL
and	NULL
monocytic	NULL
U937	NULL
cells	NULL
.	NULL

The	NULL
results	NULL
of	NULL
Northern	NULL
blot	NULL
analysis	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
showed	NULL
inducible	NULL
expression	NULL
of	NULL
the	NULL
ISG15	NULL
gene	NULL
in	NULL
all	NULL
cell	NULL
lines	NULL
except	NULL
A3.01	NULL
cells	NULL
,	NULL
which	NULL
are	NULL
rather	NULL
insensitive	NULL
to	NULL
the	NULL
IFNA	NULL
effect	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
verify	NULL
that	NULL
the	NULL
ISRE	NULL
present	NULL
in	NULL
the	NULL
promoter	NULL
region	NULL
of	NULL
ISG15	NULL
at	NULL
positions	NULL
-111	NULL
to	NULL
-94	NULL
is	NULL
sufficient	NULL
to	NULL
confer	NULL
an	NULL
IFN	NULL
response	NULL
in	NULL
cells	NULL
other	NULL
than	NULL
fibroblasts	NULL
,	NULL
the	NULL
promoter	NULL
regulatory	NULL
region	NULL
(	NULL
-366	NULL
to	NULL
+44	NULL
)	NULL
of	NULL
the	NULL
ISG15	NULL
gene	NULL
was	NULL
inserted	NULL
upstream	NULL
of	NULL
the	NULL
CAT	NULL
reporter	NULL
gene	NULL
.	NULL

This	NULL
construct	NULL
was	NULL
transfected	NULL
into	NULL
HeLa	NULL
,	NULL
CEM-174	NULL
,	NULL
or	NULL
U937	NULL
cells	NULL
,	NULL
and	NULL
16	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
IFNA	NULL
for	NULL
24	NULL
h	NULL
and	NULL
CAT	NULL
activity	NULL
was	NULL
measured	NULL
.	NULL

The	NULL
ISG15	NULL
promoter	NULL
conferred	NULL
IFN	NULL
response	NULL
to	NULL
the	NULL
reporter	NULL
gene	NULL
in	NULL
all	NULL
three	NULL
cell	NULL
lines	NULL
tested	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
and	NULL
6	NULL
)	NULL
.	NULL

A	NULL
plasmid	NULL
containing	NULL
three	NULL
copies	NULL
of	NULL
ISRE	NULL
5	NULL
'	NULL
of	NULL
(	NULL
=119	NULL
)	NULL
HIV-1	NULL
LTR-CAT	NULL
was	NULL
also	NULL
induced	NULL
in	NULL
U937	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
and	NULL
CEM-174	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
although	NULL
less	NULL
efficiently	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
while	NULL
ISRE	NULL
alone	NULL
can	NULL
function	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
and	NULL
monocytes	NULL
,	NULL
additional	NULL
cis	NULL
Vou	NULL
.	NULL

69	NULL
,	NULL
1995	NULL
*	NULL
@	NULL
10	NULL
P	NULL
3	NULL
40	NULL
50600	NULL
7	NULL
O8	NULL
9	NULL
10	NULL
e	NULL
o	NULL
CEM-174	NULL
Jurkat	NULL
Hela	NULL
_	NULL
A3.01	NULL
U937	NULL
B	NULL
[	NULL
-	NULL
1SG	NULL
Ts	NULL
PROM	NULL
J-	NULL
__GAr	NULL
__	NULL
]	NULL
Cell	NULL
type	NULL
|	NULL
-	NULL
HeLa	NULL
CEM-174	NULL
u937	NULL
IFN-A	NULL
-	NULL
[	NULL
+	NULL
[	NULL
-	NULL
[	NULL
+	NULL
*C	NULL
-	NULL
0	NULL
#	NULL
6	NULL
e	NULL
o	NULL
o	NULL
0	NULL
0	NULL
0	NULL
7	NULL
11	NULL
e	NULL
[	NULL
s	NULL
[	NULL
4	NULL
|	NULL
s	NULL
[	NULL
s	NULL
<	NULL
|_s	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

IFN	NULL
induces	NULL
expression	NULL
of	NULL
the	NULL
endogenous	NULL
ISG15	NULL
gene	NULL
and	NULL
transfected	NULL
ISG15	NULL
CAT	NULL
plasmids	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
and	NULL
macrophages	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Northern	NULL
blot	NULL
analysis	NULL
of	NULL
the	NULL
ISG15	NULL
mRNA	NULL
in	NULL
HeLa	NULL
,	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
monocytes	NULL
treated	NULL
with	NULL
human	NULL
IFNA2	NULL
.	NULL

The	NULL
arrow	NULL
indicates	NULL
the	NULL
position	NULL
of	NULL
ISG15	NULL
mRNA	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Transient	NULL
transfection	NULL
assay	NULL
with	NULL
plasmids	NULL
(	NULL
shown	NULL
schematically	NULL
)	NULL
containing	NULL
either	NULL
the	NULL
ISG15	NULL
promoter	NULL
(	NULL
ISG	NULL
15	NULL
PROM	NULL
)	NULL
or	NULL
the	NULL
(	NULL
-119	NULL
)	NULL
HIV-1	NULL
LTR	NULL
promoter	NULL
with	NULL
three	NULL
copies	NULL
of	NULL
ISREs	NULL
inserted	NULL
5	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
.	NULL

Lanes	NULL
1	NULL
through	NULL
6	NULL
,	NULL
cells	NULL
transfected	NULL
with	NULL
ISG15	NULL
CAT	NULL
;	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
,	NULL
cells	NULL
transfected	NULL
with	NULL
(	NULL
ISRE	NULL
)	NULL
;	NULL
(	NULL
-119	NULL
)	NULL
HIV-1	NULL
LTR-CAT	NULL
.	NULL

The	NULL
percentages	NULL
of	NULL
conversion	NULL
of	NULL
the	NULL
uninduced	NULL
and	NULL
IFNA-induced	NULL
ISRE-HIV-1	NULL
LTR-CAT	NULL
plasmid	NULL
were	NULL
4	NULL
to	NULL
8	NULL
and	NULL
55	NULL
to	NULL
60	NULL
,	NULL
respectively	NULL
.	NULL

element	NULL
(	NULL
s	NULL
)	NULL
in	NULL
the	NULL
ISG15	NULL
promoter	NULL
region	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
magnitude	NULL
of	NULL
induction	NULL
.	NULL

Activity	NULL
of	NULL
ISG15-HIV-1	NULL
LTR	NULL
chimeric	NULL
promoter	NULL
is	NULL
enhanced	NULL
by	NULL
Tat	NULL
.	NULL

Since	NULL
a	NULL
higher	NULL
response	NULL
to	NULL
IFNA	NULL
was	NULL
observed	NULL
when	NULL
the	NULL
ISG15	NULL
promoter	NULL
,	NULL
rather	NULL
than	NULL
multiple	NULL
copies	NULL
of	NULL
ISRE	NULL
,	NULL
was	NULL
linked	NULL
upstream	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
,	NULL
in	NULL
the	NULL
following	NULL
studies	NULL
,	NULL
an	NULL
ISG15	NULL
promoter	NULL
(	NULL
-366	NULL
to	NULL
-36	NULL
)	NULL
lacking	NULL
the	NULL
TATA	NULL
box	NULL
inserted	NULL
upstream	NULL
of	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR-CAT	NULL
was	NULL
used	NULL
.	NULL

The	NULL
inducibility	NULL
of	NULL
this	NULL
plasmid	NULL
by	NULL
IFNA	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
Tat	NULL
was	NULL
first	NULL
examined	NULL
in	NULL
CEM-174	NULL
cells	NULL
.	NULL

Figure	NULL
3	NULL
shows	NULL
that	NULL
while	NULL
transfected	NULL
ISG15	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR-CAT	NULL
plasmid	NULL
was	NULL
not	NULL
expressed	NULL
constitutively	NULL
in	NULL
these	NULL
cells	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
treatment	NULL
of	NULL
transfected	NULL
cells	NULL
with	NULL
exogenous	NULL
IFNA2	NULL
resulted	NULL
in	NULL
an	NULL
approximately	NULL
4-fold	NULL
increase	NULL
of	NULL
CAT	NULL
activity	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
,	NULL
while	NULL
Tat-induced	NULL
expression	NULL
of	NULL
ISG15	NULL
HIV-1	NULL
LTR-CAT	NULL
plasmid	NULL
was	NULL
about	NULL
10-fold	NULL
higher	NULL
than	NULL
expression	NULL
of	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR-CAT	NULL
plasmid	NULL
(	NULL
lanes	NULL
4	NULL
and	NULL
7	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
enhancer	NULL
(	NULL
s	NULL
)	NULL
in	NULL
the	NULL
ISG15	NULL
promoter	NULL
region	NULL
can	NULL
cooperate	NULL
with	NULL
Tat	NULL
protein	NULL
.	NULL

However	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
exogenous	NULL
IFN	NULL
did	NULL
not	NULL
increase	NULL
significantly	NULL
(	NULL
twofold	NULL
)	NULL
CAT	NULL
levels	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Tat	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
Tat-mediated	NULL
transactivation	NULL
of	NULL
this	NULL
promoter	NULL
is	NULL
much	NULL
stronger	NULL
than	NULL
the	NULL
stimulation	NULL
of	NULL
ISRE	NULL
induced	NULL
by	NULL
ISGF-3	NULL
complex	NULL
(	NULL
30	NULL
)	NULL
.	NULL

ISG15-HIV	NULL
LTR-CAT	NULL
was	NULL
also	NULL
transfected	NULL
into	NULL
U937	NULL
cells	NULL
.	NULL

In	NULL
these	NULL
cells	NULL
,	NULL
transactivation	NULL
of	NULL
the	NULL
chimeric	NULL
promoter	NULL
by	NULL
Tat	NULL
was	NULL
about	NULL
4-	NULL
and	NULL
20-fold	NULL
higher	NULL
than	NULL
the	NULL
(	NULL
-119	NULL
)	NULL
and	NULL
(	NULL
-83	NULL
)	NULL
SELECTIVE	NULL
EXPRESSION	NULL
OF	NULL
A	NULL
TRANSDUCED	NULL
IFN	NULL
GENE	NULL
113	NULL
A	NULL
L_	NULL
ISG	NULL
15	NULL
_	NULL
|	NULL
TATA	NULL
|	NULL
TAR	NULL
CAT	NULL
Reporter	NULL
(	NULL
-119	NULL
)	NULL
HIV	NULL
LTR|	NULL
(	NULL
-83	NULL
)	NULL
HIV	NULL
LTR	NULL
-	NULL
+	NULL
=	NULL
+	NULL
-	NULL
[	NULL
+	NULL
[	NULL
-	NULL
|	NULL
+	NULL
&	NULL
@	NULL
6	NULL
[	NULL
r	NULL
|	NULL
s	NULL
I§G15	NULL
(	NULL
-83	NULL
)	NULL
HIV	NULL
LTR	NULL
Tat	NULL
IFNA	NULL
=	NULL
#	NULL
@	NULL
||	NULL
:	NULL
5	NULL
CI	NULL
Control	NULL
PMA	NULL
REW	NULL
TNF-A	NULL
Fold	NULL
Activation	NULL
an	NULL
ISG15	NULL
(	NULL
-83	NULL
)	NULL
HIV	NULL
LTR	NULL
(	NULL
-119	NULL
)	NULL
HIV	NULL
LTR	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Linkage	NULL
of	NULL
the	NULL
5'-flanking	NULL
sequences	NULL
of	NULL
the	NULL
ISG15	NULL
gene	NULL
can	NULL
partially	NULL
restore	NULL
Tat-mediated	NULL
activation	NULL
of	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
in	NULL
CEM-174	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
ISG15	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR-CAT	NULL
plasmid	NULL
is	NULL
shown	NULL
schematically	NULL
.	NULL

CEM-174	NULL
cells	NULL
were	NULL
transfected	NULL
(	NULL
+	NULL
)	NULL
with	NULL
a	NULL
given	NULL
plasmid	NULL
and	NULL
induced	NULL
(	NULL
+	NULL
)	NULL
or	NULL
not	NULL
induced	NULL
(	NULL
-	NULL
)	NULL
with	NULL
recombinant	NULL
human	NULL
IFNA	NULL
(	NULL
500	NULL
U/ml	NULL
)	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

CAT	NULL
activities	NULL
were	NULL
measured	NULL
40	NULL
h	NULL
after	NULL
transfection	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Activation	NULL
of	NULL
(	NULL
-119	NULL
)	NULL
HIV-1	NULL
LTR	NULL
and	NULL
ISG15	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR-CAT	NULL
expression	NULL
by	NULL
TNF-a	NULL
in	NULL
U937	NULL
cells	NULL
.	NULL

U937	NULL
cells	NULL
(	NULL
10	NULL
``	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
either	NULL
(	NULL
-119	NULL
)	NULL
HIV-1	NULL
LTR-CAT	NULL
or	NULL
ISG15	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR-CAT	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
and	NULL
then	NULL
divided	NULL
into	NULL
two	NULL
plates	NULL
.	NULL

Twenty-four	NULL
hours	NULL
after	NULL
transfection	NULL
,	NULL
recombinant	NULL
human	NULL
TNF-	NULL
«	NULL
(	NULL
TNF-A	NULL
)	NULL
(	NULL
100	NULL
U/ml	NULL
;	NULL
Genentech	NULL
,	NULL
South	NULL
San	NULL
Francisco	NULL
,	NULL
Calif.	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
medium	NULL
while	NULL
the	NULL
other	NULL
plate	NULL
was	NULL
used	NULL
as	NULL
a	NULL
uninduced	NULL
control	NULL
.	NULL

Incubation	NULL
was	NULL
continued	NULL
for	NULL
a	NULL
further	NULL
20	NULL
h	NULL
before	NULL
the	NULL
CAT	NULL
assay	NULL
was	NULL
performed	NULL
.	NULL

HIV-1	NULL
LTRs	NULL
,	NULL
respectively	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
transfected	NULL
cells	NULL
with	NULL
IFNA	NULL
did	NULL
not	NULL
greatly	NULL
affect	NULL
the	NULL
Tat-mediated	NULL
activation	NULL
of	NULL
(	NULL
-119	NULL
)	NULL
HIV-1	NULL
LTR	NULL
and	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
,	NULL
while	NULL
it	NULL
slightly	NULL
stimulated	NULL
the	NULL
expression	NULL
of	NULL
ISG15	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
modified	NULL
HIV-1	NULL
LTR	NULL
by	NULL
cytokines	NULL
was	NULL
also	NULL
tested	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
(	NULL
-119	NULL
)	NULL
HIV-1	NULL
LTR	NULL
,	NULL
the	NULL
ISG15	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
could	NULL
not	NULL
be	NULL
activated	NULL
by	NULL
TNF-a	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
or	NULL
IL-1	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
modified	NULL
HIV-1	NULL
LTR	NULL
is	NULL
not	NULL
sensitive	NULL
to	NULL
NF-	NULL
«	NULL
B-mediated	NULL
transactivation	NULL
.	NULL

Surprisingly	NULL
,	NULL
however	NULL
,	NULL
this	NULL
promoter	NULL
was	NULL
still	NULL
responsive	NULL
to	NULL
PMA-mediated	NULL
stimulation	NULL
,	NULL
indicating	NULL
that	NULL
not	NULL
only	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
,	NULL
but	NULL
as	NULL
shown	NULL
in	NULL
megakaryocytes	NULL
(	NULL
50	NULL
)	NULL
,	NULL
additional	NULL
alternative	NULL
pathways	NULL
are	NULL
involved	NULL
in	NULL
PMA-mediated	NULL
stimulation	NULL
.	NULL

Tat-induced	NULL
IFN	NULL
synthesis	NULL
in	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
retrovirus	NULL
vectors	NULL
containing	NULL
the	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
and	NULL
ISG15-HIV-1	NULL
LTR	NULL
hybrid	NULL
genes	NULL
.	NULL

Since	NULL
the	NULL
ultimate	NULL
goal	NULL
of	NULL
this	NULL
study	NULL
was	NULL
to	NULL
obtain	NULL
a	NULL
promoter	NULL
that	NULL
could	NULL
express	NULL
the	NULL
IFN	NULL
gene	NULL
selectively	NULL
in	NULL
HIV-l-infected	NULL
cells	NULL
,	NULL
we	NULL
further	NULL
tested	NULL
114	NULL
SU	NULL
ET	NULL
AL	NULL
.	NULL

TABLE	NULL
1	NULL
.	NULL

Enhancement	NULL
of	NULL
Tat-mediated	NULL
activation	NULL
of	NULL
the	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
in	NULL
U937	NULL
cells	NULL
by	NULL
linkage	NULL
of	NULL
cis	NULL
sequences	NULL
of	NULL
the	NULL
ISG15	NULL
promoter	NULL
``	NULL
Reporter	NULL
Cotransfepted	NULL
IFNA®	NULL
%	NULL
Conversion	NULL
plasmid	NULL
(	NULL
-119	NULL
)	NULL
HIV-1	NULL
LTR	NULL
None	NULL
-	NULL
0.5	NULL
None	NULL
+	NULL
0.6	NULL
pllMexiafIII	NULL
-	NULL
86.8°	NULL
pllMexiafIII	NULL
+	NULL
53.8	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
None	NULL
-	NULL
0.3	NULL
None	NULL
+	NULL
0.3	NULL
pllMexiafIII	NULL
-	NULL
16.7	NULL
pllMexiafIII	NULL
+	NULL
12.7	NULL
ISG15	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
None	NULL
-	NULL
0.6	NULL
None	NULL
+	NULL
5.3	NULL
pllMexiafIII	NULL
-	NULL
316.6°	NULL
pllMexiafIII	NULL
+	NULL
443.3°	NULL
``	NULL
U937	NULL
cells	NULL
were	NULL
transfected	NULL
and	NULL
treated	NULL
with	NULL
human	NULL
IFNA	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

*	NULL
-	NULL
,	NULL
IFNA	NULL
absent	NULL
;	NULL
+	NULL
,	NULL
IFNA	NULL
present	NULL
.	NULL

©	NULL
Reduced	NULL
amounts	NULL
of	NULL
cell	NULL
extract	NULL
and	NULL
reaction	NULL
times	NULL
were	NULL
used	NULL
for	NULL
the	NULL
CAT	NULL
assay	NULL
when	NULL
acetylation	NULL
of	NULL
CAT	NULL
was	NULL
higher	NULL
than	NULL
60	NULL
%	NULL
.	NULL

All	NULL
the	NULL
values	NULL
shown	NULL
were	NULL
normalized	NULL
to	NULL
a	NULL
reaction	NULL
time	NULL
of	NULL
30	NULL
min	NULL
with	NULL
50	NULL
ug	NULL
of	NULL
cytosol	NULL
.	NULL

whether	NULL
the	NULL
ISG15-HIV-1	NULL
LTR	NULL
hybrid	NULL
promoter	NULL
could	NULL
be	NULL
used	NULL
to	NULL
direct	NULL
high	NULL
levels	NULL
of	NULL
IFN	NULL
synthesis	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Tat	NULL
proteins	NULL
.	NULL

We	NULL
inserted	NULL
the	NULL
ISG15-HIV-1	NULL
LTR	NULL
chimeric	NULL
promoter	NULL
upstream	NULL
of	NULL
the	NULL
human	NULL
IFNA2	NULL
gene	NULL
,	NULL
and	NULL
this	NULL
hybrid	NULL
gene	NULL
was	NULL
then	NULL
introduced	NULL
into	NULL
pLJenh	NULL
:	NULL
retrovirus	NULL
vector	NULL
which	NULL
has	NULL
a	NULL
deletion	NULL
in	NULL
the	NULL
enhancer	NULL
region	NULL
of	NULL
its	NULL
3	NULL
'	NULL
LTR	NULL
(	NULL
13	NULL
,	NULL
14	NULL
)	NULL
.	NULL

Similar	NULL
vectors	NULL
containing	NULL
either	NULL
the	NULL
entire	NULL
(	NULL
-119	NULL
)	NULL
HIV-1	NULL
ISG	NULL
]	NULL
-366	NULL
to	NULL
-36	NULL
of	NULL
ISG15	NULL
[	NULL
HIV	NULL
]	NULL
-83	NULL
to	NULL
+80	NULL
of	NULL
HIV-1	NULL
LTR	NULL
CCZHV	NULL
CITI	NULL
+451	NULL
to	NULL
+80	NULL
of	NULL
HIV-1	NULL
LTR	NULL
human	NULL
IFN	NULL
A2	NULL
J.	NULL
ViroL	NULL
.	NULL

LTR	NULL
or	NULL
the	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR-IFNA	NULL
hybrid	NULL
gene	NULL
were	NULL
used	NULL
as	NULL
the	NULL
positive	NULL
or	NULL
negative	NULL
control	NULL
,	NULL
respectively	NULL
.	NULL

Synthesis	NULL
of	NULL
IFNAZ	NULL
from	NULL
these	NULL
retrovirus	NULL
vectors	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
Tat	NULL
protein	NULL
was	NULL
first	NULL
analyzed	NULL
in	NULL
Vero	NULL
cells	NULL
,	NULL
which	NULL
contain	NULL
a	NULL
homozygous	NULL
deletion	NULL
of	NULL
type	NULL
1	NULL
IFN	NULL
genes	NULL
(	NULL
IFNA	NULL
and	NULL
IFNB	NULL
)	NULL
,	NULL
and	NULL
therefore	NULL
,	NULL
any	NULL
IFN	NULL
synthesis	NULL
in	NULL
these	NULL
cells	NULL
is	NULL
encoded	NULL
by	NULL
the	NULL
transduced	NULL
IFN	NULL
gene	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Culture	NULL
medium	NULL
was	NULL
collected	NULL
48	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
and	NULL
levels	NULL
of	NULL
biologically	NULL
active	NULL
IFNA	NULL
were	NULL
measured	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Tat	NULL
protein	NULL
,	NULL
the	NULL
amount	NULL
of	NULL
IFNA	NULL
produced	NULL
from	NULL
the	NULL
vector	NULL
containing	NULL
the	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR-IFNA	NULL
hybrid	NULL
gene	NULL
inserted	NULL
in	NULL
the	NULL
opposite	NULL
(	NULL
=	NULL
)	NULL
orientation	NULL
was	NULL
twofold	NULL
higher	NULL
than	NULL
the	NULL
amount	NULL
obtained	NULL
from	NULL
the	NULL
vector	NULL
carrying	NULL
the	NULL
hybrid	NULL
gene	NULL
inserted	NULL
in	NULL
the	NULL
forward	NULL
(	NULL
+	NULL
)	NULL
orientation	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
Tat	NULL
,	NULL
a	NULL
4-fold	NULL
increase	NULL
of	NULL
IFNA	NULL
synthesis	NULL
was	NULL
observed	NULL
from	NULL
the	NULL
vector	NULL
containing	NULL
the	NULL
forward-oriented	NULL
hybrid	NULL
gene	NULL
,	NULL
while	NULL
more	NULL
than	NULL
a	NULL
20-fold	NULL
increase	NULL
of	NULL
IFN	NULL
synthesis	NULL
was	NULL
observed	NULL
from	NULL
the	NULL
vector	NULL
carrying	NULL
the	NULL
hybrid	NULL
gene	NULL
in	NULL
the	NULL
reverse	NULL
orientation	NULL
.	NULL

Orientation-dependent	NULL
activation	NULL
of	NULL
an	NULL
inducible	NULL
promoter	NULL
in	NULL
this	NULL
retrovirus	NULL
vector	NULL
was	NULL
also	NULL
observed	NULL
in	NULL
our	NULL
previous	NULL
studies	NULL
(	NULL
4	NULL
,	NULL
14	NULL
)	NULL
and	NULL
is	NULL
presumably	NULL
due	NULL
to	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
enhancer	NULL
in	NULL
the	NULL
3	NULL
'	NULL
adjacent	NULL
simian	NULL
virus	NULL
40	NULL
promoter	NULL
directing	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
neomycin-resistant	NULL
gene	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Linkage	NULL
of	NULL
the	NULL
5'-flanking	NULL
region	NULL
of	NULL
ISG15	NULL
gene	NULL
to	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
resulted	NULL
in	NULL
a	NULL
four-	NULL
to	NULL
fivefold	NULL
increase	NULL
of	NULL
a	NULL
constitutively	NULL
produced	NULL
IFNA	NULL
from	NULL
the	NULL
retrovirus	NULL
constructs	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
ISRE	NULL
enhancer	NULL
present	NULL
in	NULL
the	NULL
linked	NULL
ISG15	NULL
DNA	NULL
fragment	NULL
functions	NULL
in	NULL
Vero	NULL
cells	NULL
.	NULL

When	NULL
an	NULL
ISG15-LTR-IFNA2Z	NULL
hybrid	NULL
gene	NULL
was	NULL
inserted	NULL
in	NULL
the	NULL
opposite	NULL
orientation	NULL
in	NULL
this	NULL
vector	NULL
,	NULL
a	NULL
relative	NULL
magnitude	NULL
of	NULL
transactivation	NULL
(	NULL
16-fold	NULL
)	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
obtained	NULL
from	NULL
the	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
.	NULL

However	NULL
,	NULL
when	NULL
an	NULL
ISG15-LTR-IFNA2	NULL
hybrid	NULL
gene	NULL
was	NULL
inserted	NULL
in	NULL
the	NULL
forward	NULL
IFN	NULL
Production	NULL
(	NULL
Unit/ml	NULL
)	NULL
Vero	NULL
U937	NULL
Jurkat	NULL
-Tat	NULL
-	NULL
+Tat	NULL
-Tat	NULL
-	NULL
+Tat	NULL
~-Tat	NULL
_	NULL
+Tat	NULL
6.5	NULL
28	NULL
6.3	NULL
-	NULL
50.7	NULL
<	NULL
1	NULL
50	NULL
12	NULL
256	NULL
15.8	NULL
112	NULL
<	NULL
1	NULL
100	NULL
35	NULL
832	NULL
5.4	NULL
180	NULL
<	NULL
1	NULL
30	NULL
52	NULL
800	NULL
16	NULL
608	NULL
<	NULL
1	NULL
250	NULL
26	NULL
-	NULL
448	NULL
12	NULL
-	NULL
352	NULL
-	NULL
100	NULL
1000	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Activation	NULL
of	NULL
IFNA2	NULL
synthesis	NULL
by	NULL
Tat	NULL
in	NULL
Vero	NULL
,	NULL
U937	NULL
,	NULL
and	NULL
Jurkat	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
retrovirus	NULL
vectors	NULL
containing	NULL
the	NULL
modified	NULL
HIV-1	NULL
LTR-IFNA	NULL
gene	NULL
.	NULL

The	NULL
HIV-1	NULL
LTR-IFNA	NULL
hybrid	NULL
genes	NULL
inserted	NULL
into	NULL
the	NULL
pLJenh~	NULL
vector	NULL
(	NULL
13	NULL
)	NULL
were	NULL
transfected	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
+Tat	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
-Tat	NULL
)	NULL
of	NULL
plMIextafIII	NULL
into	NULL
Vero	NULL
,	NULL
U937	NULL
,	NULL
or	NULL
Jurkat	NULL
cells	NULL
,	NULL
and	NULL
IFN	NULL
levels	NULL
in	NULL
medium	NULL
of	NULL
transfected	NULL
cells	NULL
were	NULL
measured	NULL
48	NULL
h	NULL
after	NULL
transfection	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
all	NULL
the	NULL
plasmids	NULL
contain	NULL
the	NULL
neo	NULL
gene	NULL
under	NULL
regulation	NULL
of	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
early	NULL
promoter	NULL
region	NULL
inserted	NULL
3	NULL
'	NULL
of	NULL
the	NULL
IFN	NULL
gene	NULL
.	NULL

Vou	NULL
.	NULL

69	NULL
,	NULL
1995	NULL
.	NULL

'+	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Tat-inducible	NULL
expression	NULL
of	NULL
IFNAZ	NULL
mRNA	NULL
in	NULL
transfected	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
transfected	NULL
with	NULL
retrovirus	NULL
vector	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
plMicx-tat	NULL
[	NULL
II	NULL
plasmid	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
and	NULL
total	NULL
RNA	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
isolated	NULL
from	NULL
U937	NULL
cells	NULL
48	NULL
h	NULL
after	NULL
transfection	NULL
was	NULL
analyzed	NULL
by	NULL
Northern	NULL
blot	NULL
hybridization	NULL
with	NULL
human	NULL
IFNA2	NULL
antisense	NULL
riboprobes	NULL
.	NULL

Lanes	NULL
1	NULL
and	NULL
2	NULL
,	NULL
RNAs	NULL
from	NULL
cells	NULL
transfected	NULL
with	NULL
vector	NULL
II	NULL
;	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
,	NULL
RNAs	NULL
from	NULL
cells	NULL
transfected	NULL
with	NULL
vector	NULL
IV	NULL
;	NULL
lanes	NULL
5	NULL
and	NULL
6	NULL
,	NULL
RNAs	NULL
from	NULL
cells	NULL
transfected	NULL
with	NULL
vector	NULL
I.	NULL
Vectors	NULL
I	NULL
,	NULL
III	NULL
,	NULL
and	NULL
IV	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

In	NULL
lanes	NULL
2	NULL
,	NULL
4	NULL
,	NULL
and	NULL
6	NULL
,	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
plextefIII	NULL
.	NULL

The	NULL
arrow	NULL
indicates	NULL
the	NULL
position	NULL
of	NULL
IFNA2	NULL
mRNA	NULL
.	NULL

orientation	NULL
into	NULL
this	NULL
retrovirus	NULL
vector	NULL
,	NULL
Tat-mediated	NULL
expression	NULL
of	NULL
IFN	NULL
gene	NULL
was	NULL
much	NULL
higher	NULL
(	NULL
20-fold	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
than	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
5-fold	NULL
)	NULL
of	NULL
a	NULL
ISG15	NULL
fragment	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
presence	NULL
of	NULL
heterologous	NULL
enhancer	NULL
(	NULL
ISG15	NULL
or	NULL
simian	NULL
virus	NULL
40	NULL
)	NULL
5	NULL
of	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
enhances	NULL
Tat-mediated	NULL
transactivation	NULL
.	NULL

Production	NULL
of	NULL
IFNA	NULL
from	NULL
these	NULL
retrovirus	NULL
vectors	NULL
was	NULL
also	NULL
analyzed	NULL
in	NULL
monocyte	NULL
(	NULL
U937	NULL
)	NULL
and	NULL
T-cell	NULL
(	NULL
Jurkat	NULL
)	NULL
lines	NULL
.	NULL

In	NULL
U937	NULL
cells	NULL
,	NULL
constitutive	NULL
levels	NULL
of	NULL
IFN	NULL
were	NULL
very	NULL
low	NULL
(	NULL
5	NULL
to	NULL
16	NULL
U	NULL
)	NULL
and	NULL
were	NULL
not	NULL
increased	NULL
by	NULL
a	NULL
linkage	NULL
of	NULL
the	NULL
ISG15	NULL
DNA	NULL
fragment	NULL
to	NULL
the	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
;	NULL
however	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
ISG15	NULL
greatly	NULL
facilitated	NULL
Tat-activated	NULL
synthesis	NULL
of	NULL
IFN	NULL
,	NULL
and	NULL
about	NULL
a	NULL
38-fold	NULL
increase	NULL
in	NULL
IFN	NULL
synthesis	NULL
was	NULL
observed	NULL
.	NULL

The	NULL
high	NULL
level	NULL
of	NULL
transactivation	NULL
of	NULL
this	NULL
hybrid	NULL
promoter	NULL
was	NULL
confirmed	NULL
when	NULL
the	NULL
levels	NULL
of	NULL
IFNA	NULL
mRNA	NULL
were	NULL
analyzed	NULL
by	NULL
Northern	NULL
blot	NULL
hybridization	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

The	NULL
relative	NULL
levels	NULL
of	NULL
IFNA	NULL
mRNA	NULL
directed	NULL
by	NULL
the	NULL
ISG15-LTR	NULL
hybrid	NULL
promoters	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Tat	NULL
were	NULL
about	NULL
10-fold	NULL
higher	NULL
than	NULL
the	NULL
levels	NULL
encoded	NULL
by	NULL
the	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
compare	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
with	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
no	NULL
constitutive	NULL
IFNA	NULL
synthesis	NULL
could	NULL
be	NULL
detected	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Tat	NULL
and	NULL
neither	NULL
the	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
nor	NULL
ISG15-HIV-1	NULL
LTR-IFNA	NULL
hybrid	NULL
were	NULL
expressed	NULL
constitutively	NULL
and	NULL
no	NULL
IFN	NULL
activity	NULL
could	NULL
be	NULL
detected	NULL
in	NULL
the	NULL
medium	NULL
.	NULL

Only	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Tat	NULL
protein	NULL
were	NULL
these	NULL
promoters	NULL
transcriptionally	NULL
activated	NULL
.	NULL

Similarly	NULL
,	NULL
as	NULL
in	NULL
U937	NULL
cells	NULL
,	NULL
plasmids	NULL
containing	NULL
the	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
or	NULL
ISG15-HIV-1	NULL
LTR-IFNA	NULL
hybrid	NULL
gene	NULL
inserted	NULL
in	NULL
the	NULL
opposite	NULL
orientation	NULL
were	NULL
induced	NULL
by	NULL
Tat	NULL
more	NULL
efficiently	NULL
than	NULL
when	NULL
the	NULL
hybrid	NULL
gene	NULL
was	NULL
inserted	NULL
in	NULL
the	NULL
forward	NULL
orientation	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
constitutive	NULL
expression	NULL
of	NULL
the	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
and	NULL
ISG15-HIV-1	NULL
LTR	NULL
is	NULL
determined	NULL
by	NULL
the	NULL
host	NULL
factors	NULL
and	NULL
that	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
transient	NULL
expression	NULL
of	NULL
a	NULL
modified	NULL
HIV-1	NULL
LTR	NULL
is	NULL
strictly	NULL
dependent	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
Tat	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
HIV-1	NULL
LTR	NULL
promoter	NULL
containing	NULL
the	NULL
enhancer	NULL
region	NULL
(	NULL
-451	NULL
HIV	NULL
LTR	NULL
)	NULL
was	NULL
expressed	NULL
constitutively	NULL
in	NULL
Jurkat	NULL
cells	NULL
even	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Tat	NULL
and	NULL
relatively	NULL
high	NULL
levels	NULL
(	NULL
100	NULL
U	NULL
)	NULL
of	NULL
IFNA	NULL
could	NULL
be	NULL
detected	NULL
in	NULL
the	NULL
medium	NULL
.	NULL

Yields	NULL
of	NULL
the	NULL
recombinant	NULL
virus	NULL
are	NULL
inhibited	NULL
by	NULL
IFNA	NULL
synthesized	NULL
in	NULL
the	NULL
packaging	NULL
line	NULL
.	NULL

To	NULL
be	NULL
able	NULL
to	NULL
transduce	NULL
effectively	NULL
the	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
or	NULL
ISG15-HIV-1	NULL
LTR-IFNA	NULL
hybrid	NULL
genes	NULL
into	NULL
T	NULL
cells	NULL
and	NULL
monocytes	NULL
,	NULL
we	NULL
have	NULL
attempted	NULL
to	NULL
package	NULL
these	NULL
hybrid	NULL
genes	NULL
into	NULL
amphotropic	NULL
virus	NULL
pseudo-types	NULL
.	NULL

Retrovirus	NULL
vectors	NULL
containing	NULL
various	NULL
HIV-1	NULL
LTR	NULL
hybrid	NULL
genes	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
were	NULL
transfected	NULL
into	NULL
PA317	NULL
cells	NULL
,	NULL
neomycin-resistant	NULL
clones	NULL
were	NULL
selected	NULL
,	NULL
and	NULL
the	NULL
levels	NULL
of	NULL
a	NULL
recombinant	NULL
virus	NULL
in	NULL
medium	NULL
were	NULL
analyzed	NULL
by	NULL
a	NULL
RT	NULL
assay	NULL
and	NULL
by	NULL
the	NULL
titration	NULL
of	NULL
the	NULL
recombinant	NULL
virus	NULL
on	NULL
NIH	NULL
3T3	NULL
cells	NULL
and	NULL
counting	NULL
the	NULL
neomycin-resistant	NULL
colonies	NULL
.	NULL

While	NULL
the	NULL
levels	NULL
of	NULL
SELECTIVE	NULL
EXPRESSION	NULL
OF	NULL
A	NULL
TRANSDUCED	NULL
IFN	NULL
GENE	NULL
115	NULL
RT	NULL
in	NULL
the	NULL
medium	NULL
of	NULL
transfected	NULL
cells	NULL
were	NULL
about	NULL
10-	NULL
to	NULL
15-fold	NULL
higher	NULL
than	NULL
in	NULL
the	NULL
untransfected	NULL
cells	NULL
,	NULL
a	NULL
titration	NULL
on	NULL
NIH	NULL
3T3	NULL
cells	NULL
showed	NULL
that	NULL
only	NULL
about	NULL
100	NULL
to	NULL
500	NULL
particles	NULL
per	NULL
ml	NULL
are	NULL
present	NULL
in	NULL
the	NULL
medium	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
PA317	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
vector	NULL
alone	NULL
produced	NULL
about	NULL
5	NULL
X	NULL
10°	NULL
to	NULL
5	NULL
x	NULL
10°	NULL
neomycin-resistant	NULL
particles	NULL
per	NULL
ml	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
,	NULL
therefore	NULL
,	NULL
cloned	NULL
,	NULL
and	NULL
the	NULL
individual	NULL
clones	NULL
were	NULL
tested	NULL
for	NULL
the	NULL
production	NULL
of	NULL
recombinant	NULL
virus	NULL
,	NULL
but	NULL
no	NULL
clone	NULL
that	NULL
produced	NULL
more	NULL
than	NULL
1,000	NULL
particles	NULL
per	NULL
ml	NULL
was	NULL
identified	NULL
.	NULL

However	NULL
,	NULL
all	NULL
clones	NULL
tested	NULL
produced	NULL
low	NULL
levels	NULL
(	NULL
5	NULL
to	NULL
10	NULL
U/ml	NULL
)	NULL
of	NULL
human	NULL
IFNAZ	NULL
constitutively	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
low	NULL
packaging	NULL
efficiency	NULL
could	NULL
be	NULL
due	NULL
to	NULL
the	NULL
inability	NULL
of	NULL
this	NULL
particular	NULL
construct	NULL
to	NULL
assemble	NULL
efficiently	NULL
or	NULL
a	NULL
consequence	NULL
of	NULL
the	NULL
low	NULL
constitutive	NULL
IFNA	NULL
synthesis	NULL
in	NULL
packaging	NULL
cells	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
assembly	NULL
of	NULL
murine	NULL
retrovirus	NULL
particles	NULL
is	NULL
impaired	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IFN	NULL
(	NULL
40	NULL
)	NULL
.	NULL

To	NULL
be	NULL
able	NULL
to	NULL
distinguish	NULL
between	NULL
these	NULL
two	NULL
possibilities	NULL
,	NULL
we	NULL
transfected	NULL
into	NULL
PA317	NULL
cells	NULL
another	NULL
retrovirus	NULL
construct	NULL
,	NULL
containing	NULL
the	NULL
(	NULL
-119	NULL
)	NULL
HIV-1	NULL
LTR-IFNA	NULL
hybrid	NULL
gene	NULL
inserted	NULL
into	NULL
the	NULL
pLNL6	NULL
vector	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
a	NULL
pLJenh	NULL
:	NULL
vector	NULL
used	NULL
previously	NULL
(	NULL
14	NULL
)	NULL
,	NULL
this	NULL
vector	NULL
has	NULL
unmodified	NULL
3	NULL
'	NULL
LTR	NULL
,	NULL
and	NULL
the	NULL
recombinant	NULL
gene	NULL
is	NULL
inserted	NULL
3	NULL
'	NULL
of	NULL
the	NULL
neomycin	NULL
gene	NULL
and	NULL
is	NULL
therefore	NULL
,	NULL
effectively	NULL
expressed	NULL
from	NULL
a	NULL
spliced	NULL
mRNA	NULL
(	NULL
5	NULL
)	NULL
.	NULL

The	NULL
neomycin-resistant	NULL
colonies	NULL
were	NULL
selected	NULL
,	NULL
and	NULL
the	NULL
levels	NULL
of	NULL
virus	NULL
and	NULL
IFNA2	NULL
in	NULL
medium	NULL
of	NULL
the	NULL
individual	NULL
clones	NULL
were	NULL
tested	NULL
.	NULL

The	NULL
results	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
suggest	NULL
an	NULL
inverted	NULL
relationship	NULL
between	NULL
IFNAZ	NULL
production	NULL
and	NULL
levels	NULL
of	NULL
recombinant	NULL
virions	NULL
in	NULL
the	NULL
medium	NULL
.	NULL

The	NULL
highest	NULL
yields	NULL
of	NULL
a	NULL
recombinant	NULL
virus	NULL
were	NULL
observed	NULL
in	NULL
clones	NULL
that	NULL
did	NULL
not	NULL
synthesize	NULL
IFNAZ	NULL
efficiently	NULL
(	NULL
less	NULL
than	NULL
20	NULL
U	NULL
)	NULL
,	NULL
while	NULL
a	NULL
majority	NULL
of	NULL
the	NULL
clones	NULL
that	NULL
produced	NULL
about	NULL
50	NULL
to	NULL
300	NULL
U	NULL
of	NULL
IFNA	NULL
constitutively	NULL
yield	NULL
low	NULL
levels	NULL
of	NULL
virus	NULL
particles	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
constitutive	NULL
IFNA2	NULL
synthesis	NULL
in	NULL
the	NULL
packaging	NULL
line	NULL
interferes	NULL
with	NULL
the	NULL
assembly	NULL
of	NULL
the	NULL
recombinant	NULL
virus	NULL
.	NULL

IFN	NULL
synthesis	NULL
in	NULL
stably	NULL
transfected	NULL
T	NULL
cells	NULL
and	NULL
monocytes	NULL
and	NULL
its	NULL
effect	NULL
on	NULL
immune	NULL
functions	NULL
.	NULL

Because	NULL
of	NULL
an	NULL
inefficient	NULL
packaging	NULL
of	NULL
the	NULL
recombinant	NULL
retrovirus	NULL
vectors	NULL
in	NULL
the	NULL
amphotropic	NULL
cells	NULL
,	NULL
retrovirus	NULL
vectors	NULL
containing	NULL
the	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR-IFNAZ	NULL
and	NULL
ISG15-HIV-1	NULL
LTR-IFNA2Z	NULL
hybrid	NULL
plasmids	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
were	NULL
transduced	NULL
into	NULL
Jurkat	NULL
cells	NULL
and	NULL
U937	NULL
cells	NULL
by	NULL
electroporation	NULL
,	NULL
and	NULL
neomycin-resistant	NULL
clones	NULL
were	NULL
selected	NULL
and	NULL
tested	NULL
for	NULL
spontaneous	NULL
production	NULL
of	NULL
IFNAZ	NULL
.	NULL

While	NULL
the	NULL
pool	NULL
of	NULL
transduced	NULL
clones	NULL
produced	NULL
about	NULL
50	NULL
U	NULL
of	NULL
IFNA	NULL
per	NULL
ml	NULL
constitutively	NULL
,	NULL
the	NULL
individually	NULL
selected	NULL
transduced	NULL
U937	NULL
clones	NULL
produced	NULL
constitutively	NULL
variable	NULL
levels	NULL
of	NULL
IFNA	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

A	NULL
majority	NULL
of	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR-IFNA2-transduced	NULL
clones	NULL
(	NULL
60	NULL
to	NULL
70	NULL
%	NULL
)	NULL
produced	NULL
low	NULL
levels	NULL
(	NULL
5	NULL
to	NULL
50	NULL
U/ml	NULL
!	NULL
)	NULL

of	NULL
spontaneous	NULL
IFNA	NULL
,	NULL
while	NULL
a	NULL
small	NULL
percentage	NULL
(	NULL
5	NULL
to	NULL
20	NULL
%	NULL
)	NULL
of	NULL
U937	NULL
clones	NULL
synthesized	NULL
more	NULL
than	NULL
100	NULL
U	NULL
of	NULL
IFNA	NULL
per	NULL
ml	NULL
.	NULL

Similarly	NULL
,	NULL
70	NULL
to	NULL
76	NULL
%	NULL
of	NULL
U937	NULL
clones	NULL
containing	NULL
integrated	NULL
ISG15-HIV-1	NULL
LTR-IFNA	NULL
hybrid	NULL
gene	NULL
synthesized	NULL
low	NULL
levels	NULL
of	NULL
IFNA	NULL
(	NULL
0	NULL
to	NULL
50	NULL
U/ml	NULL
)	NULL
,	NULL
and	NULL
about	NULL
20	NULL
to	NULL
30	NULL
%	NULL
of	NULL
clones	NULL
synthesized	NULL
more	NULL
than	NULL
100	NULL
U/ml	NULL
.	NULL

These	NULL
differences	NULL
in	NULL
expression	NULL
among	NULL
individual	NULL
clones	NULL
may	NULL
be	NULL
due	NULL
to	NULL
the	NULL
number	NULL
of	NULL
integrated	NULL
copies	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
position	NULL
of	NULL
the	NULL
integration	NULL
site	NULL
.	NULL

However	NULL
,	NULL
the	NULL
levels	NULL
of	NULL
constitutively	NULL
produced	NULL
IFNA	NULL
were	NULL
generally	NULL
higher	NULL
in	NULL
U937	NULL
cells	NULL
than	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
transient	NULL
expression	NULL
assays	NULL
,	NULL
where	NULL
the	NULL
expression	NULL
of	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR-IFNA	NULL
and	NULL
ISG15-HIV-1	NULL
LTR-IFNA	NULL
plasmids	NULL
in	NULL
T	NULL
cells	NULL
was	NULL
seen	NULL
only	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Tat	NULL
,	NULL
low	NULL
levels	NULL
of	NULL
spontaneous	NULL
IFNA	NULL
synthesis	NULL
(	NULL
20	NULL
to	NULL
40	NULL
U/ml	NULL
)	NULL
could	NULL
be	NULL
detected	NULL
in	NULL
the	NULL
pool	NULL
of	NULL
transfected	NULL
clones	NULL
and	NULL
in	NULL
a	NULL
majority	NULL
of	NULL
permanently	NULL
transduced	NULL
T-cell	NULL
clones	NULL
tested	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
order	NULL
to	NULL
determine	NULL
whether	NULL
constitutive	NULL
IFNA	NULL
synthesis	NULL
interferes	NULL
with	NULL
the	NULL
T-cell	NULL
immune	NULL
functions	NULL
,	NULL
we	NULL
analyzed	NULL
and	NULL
116	NULL
SU	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
cov	NULL
.	NULL

1800	NULL
4	NULL
1600	NULL
IFN	NULL
units/ml	NULL
a	NULL
B	NULL
7000	NULL
60090	NULL
+	NULL
SCCC	NULL
Rr	NULL
o	NULL
®	NULL
CPMIm	NULL
|	NULL
co.	NULL
,	NULL
,	NULL
Packaging	NULL
Cell	NULL
Line	NULL
C	NULL
_	NULL
10000	NULL
-	NULL
I	NULL
I	NULL
eadso	NULL
4	NULL
°	NULL
i	NULL
[	NULL
s0000	NULL
|	NULL
€	NULL
20000	NULL
5	NULL
a	NULL
I	NULL
E	NULL
40000I	NULL
hi	NULL
<	NULL
5	NULL
|	NULL
|	NULL
£	NULL
I	NULL
s	NULL
|	NULL
&	NULL
}	NULL
&	NULL
s	NULL
i	NULL
Interferon	NULL
units/ml	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Relationship	NULL
between	NULL
production	NULL
of	NULL
recombinant	NULL
virus	NULL
and	NULL
IFNA2	NULL
synthesis	NULL
in	NULL
PA317	NULL
cells	NULL
transfected	NULL
with	NULL
pLNL6-A-9	NULL
plasmid	NULL
.	NULL

The	NULL
packing	NULL
line	NULL
PA317	NULL
was	NULL
transfected	NULL
with	NULL
recombinant	NULL
vector	NULL
pLNL6	NULL
,	NULL
containing	NULL
the	NULL
IFNA2	NULL
cDNA	NULL
under	NULL
the	NULL
regulation	NULL
of	NULL
(	NULL
-119	NULL
)	NULL
HIV-1	NULL
LTR	NULL
.	NULL

G418-resistant	NULL
clones	NULL
were	NULL
selected	NULL
and	NULL
grown	NULL
to	NULL
confluence	NULL
in	NULL
24-well	NULL
plates	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
biologically	NULL
active	NULL
IFNA2	NULL
(	NULL
A	NULL
)	NULL
or	NULL
recombinant	NULL
virus	NULL
(	NULL
B	NULL
)	NULL
in	NULL
the	NULL
medium	NULL
of	NULL
individual	NULL
clones	NULL
were	NULL
determined	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
relationship	NULL
between	NULL
IFNA2	NULL
synthesis	NULL
and	NULL
RT	NULL
activity	NULL
(	NULL
C	NULL
)	NULL
is	NULL
shown	NULL
.	NULL

compared	NULL
the	NULL
expression	NULL
of	NULL
IL-2	NULL
and	NULL
IL-2R	NULL
genes	NULL
in	NULL
Jurkat	NULL
cells	NULL
and	NULL
JISG3-A	NULL
cloned	NULL
cells	NULL
16	NULL
h	NULL
after	NULL
stimulation	NULL
with	NULL
PHA	NULL
and	NULL
PMA	NULL
.	NULL

It	NULL
can	NULL
be	NULL
seen	NULL
in	NULL
Fig	NULL
.	NULL

7	NULL
that	NULL
while	NULL
no	NULL
IL-2	NULL
and	NULL
IL-2R	NULL
mRNAs	NULL
can	NULL
be	NULL
detected	NULL
in	NULL
unstimulated	NULL
cells	NULL
,	NULL
the	NULL
relative	NULL
levels	NULL
of	NULL
both	NULL
of	NULL
these	NULL
mRNAs	NULL
are	NULL
comparable	NULL
in	NULL
stimulated	NULL
Jurkat	NULL
and	NULL
JISG3-A	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
show	NULL
that	NULL
constitutive	NULL
TABLE	NULL
2	NULL
.	NULL

Constitutive	NULL
synthesis	NULL
of	NULL
IFNAZ	NULL
in	NULL
transfected	NULL
U937	NULL
cells	NULL
No	NULL
.	NULL

of	NULL
clones	NULL
producing	NULL
the	NULL
following	NULL
level	NULL
(	NULL
U/ml	NULL
!	NULL
)	NULL

of	NULL
IFN/total	NULL
Promoter	NULL
Construct	NULL
``	NULL
no	NULL
.	NULL

of	NULL
clones	NULL
:	NULL
0-5	NULL
5-50	NULL
50-100	NULL
_	NULL
100-500	NULL
5	NULL
``	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
I	NULL
12/34	NULL
12/34	NULL
2/34	NULL
7/34	NULL
3	NULL
``	NULL
LTR	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
II	NULL
15/40	NULL
-	NULL
9/40	NULL
_	NULL
9/40	NULL
2/40	NULL
5	NULL
``	NULL
ISG15	NULL
HIV-1	NULL
LTR	NULL
III	NULL
7/17	NULL
-	NULL
6/17	NULL
-	NULL
3/17	NULL
1/17	NULL
3	NULL
'	NULL
ISG15	NULL
HIV-1	NULL
LTR	NULL
IV	NULL
15/40	NULL
13/40	NULL
_	NULL
7/40	NULL
5/40	NULL
*	NULL
Constructs	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

J.	NULL
ViroL	NULL
.	NULL

JISG3-A	NULL
-	NULL
JURKAT	NULL
-	NULL
oto	NULL
o-	NULL
+	NULL
PHA	NULL
+	NULL
PMA	NULL
-	NULL
ik	NULL
``	NULL
€	NULL
IL-2R	NULL
B	NULL
b	NULL
sa	NULL
€	NULL
IL-2	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Stimulation	NULL
of	NULL
expression	NULL
of	NULL
IL-2	NULL
and	NULL
IL-2RB	NULL
genes	NULL
by	NULL
PMA	NULL
and	NULL
PHA	NULL
in	NULL
Jurkat	NULL
and	NULL
JISG3-A	NULL
cells	NULL
.	NULL

Total	NULL
RNA	NULL
(	NULL
10	NULL
pg/lane	NULL
)	NULL
isolated	NULL
from	NULL
cells	NULL
(	NULL
107	NULL
)	NULL
stimulated	NULL
with	NULL
PMA	NULL
(	NULL
50	NULL
ng/m	NULL
!	NULL
)	NULL

and	NULL
PHA	NULL
(	NULL
5	NULL
pg/ml	NULL
)	NULL
for	NULL
16	NULL
h	NULL
was	NULL
analyzed	NULL
by	NULL
Northern	NULL
blot	NULL
hybridization	NULL
with	NULL
°°P-labeled	NULL
IL-2	NULL
DNA	NULL
probe	NULL
(	NULL
pcDHulIL-2	NULL
)	NULL
and	NULL
IL-2RB	NULL
DNA	NULL
probe	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
44	NULL
)	NULL
.	NULL

IFNA	NULL
synthesis	NULL
does	NULL
not	NULL
alter	NULL
the	NULL
ability	NULL
of	NULL
T	NULL
cells	NULL
to	NULL
respond	NULL
to	NULL
mitogenic	NULL
stimuli	NULL
.	NULL

HIV-1	NULL
replication	NULL
is	NULL
inhibited	NULL
in	NULL
Jurkat	NULL
and	NULL
U937	NULL
cells	NULL
containing	NULL
integrated	NULL
HIV-1	NULL
LTR-IFNA2	NULL
hybrid	NULL
plasmids	NULL
.	NULL

Replication	NULL
of	NULL
HIV-1	NULL
was	NULL
analyzed	NULL
in	NULL
a	NULL
clone	NULL
of	NULL
Jurkat	NULL
cells	NULL
permanently	NULL
transfected	NULL
with	NULL
the	NULL
retrovirus	NULL
vector	NULL
containing	NULL
the	NULL
recombinant	NULL
ISG15-HIV-1	NULL
LTR-IFNAZ	NULL
plasmids	NULL
.	NULL

The	NULL
selected	NULL
clone	NULL
(	NULL
JISG3-A	NULL
)	NULL
,	NULL
produced	NULL
low	NULL
levels	NULL
of	NULL
IFNAZ	NULL
constitutively	NULL
,	NULL
but	NULL
IFNAZ	NULL
synthesis	NULL
could	NULL
be	NULL
greatly	NULL
enhanced	NULL
upon	NULL
transfection	NULL
with	NULL
the	NULL
Tat-expressing	NULL
plasmid	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Kinetics	NULL
of	NULL
HIV-1	NULL
replication	NULL
in	NULL
Jurkat	NULL
cells	NULL
and	NULL
in	NULL
a	NULL
clone	NULL
(	NULL
JISG3-A	NULL
)	NULL
of	NULL
Jurkat	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
ISG15-LTR-IFNAZ	NULL
plasmid	NULL
(	NULL
construct	NULL
IV	NULL
in	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
are	NULL
compared	NULL
in	NULL
Fig	NULL
.	NULL

8A	NULL
.	NULL

It	NULL
can	NULL
be	NULL
seen	NULL
that	NULL
while	NULL
the	NULL
levels	NULL
of	NULL
RT	NULL
activity	NULL
in	NULL
the	NULL
medium	NULL
of	NULL
infected	NULL
Jurkat	NULL
cells	NULL
gradually	NULL
increased	NULL
,	NULL
reaching	NULL
maximum	NULL
at	NULL
10	NULL
days	NULL
postinfection	NULL
,	NULL
in	NULL
JISG3-A	NULL
cells	NULL
HIV-1	NULL
replication	NULL
was	NULL
permanently	NULL
suppressed	NULL
.	NULL

Furthermore	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
infected	NULL
Jurkat	NULL
cells	NULL
(	NULL
which	NULL
,	NULL
by	NULL
10	NULL
days	NULL
postinfection	NULL
,	NULL
started	NULL
to	NULL
show	NULL
cell	NULL
fusion	NULL
;	NULL
by	NULL
2	NULL
weeks	NULL
postinfection	NULL
,	NULL
more	NULL
than	NULL
50	NULL
%	NULL
of	NULL
the	NULL
cells	NULL
were	NULL
dead	NULL
)	NULL
,	NULL
no	NULL
cytopathic	NULL
effect	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
infected	NULL
JISG3-A	NULL
clone	NULL
,	NULL
and	NULL
the	NULL
infected	NULL
cells	NULL
were	NULL
viable	NULL
without	NULL
any	NULL
detectable	NULL
cytopathic	NULL
effect	NULL
for	NULL
a	NULL
month	NULL
postinfection	NULL
,	NULL
when	NULL
the	NULL
experiment	NULL
was	NULL
terminated	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
IFNA2	NULL
synthesized	NULL
in	NULL
infected	NULL
and	NULL
uninfected	NULL
JISG3-A	NULL
cells	NULL
were	NULL
then	NULL
analyzed	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
IFNAZ	NULL
in	NULL
uninfected	NULL
cells	NULL
during	NULL
the	NULL
first	NULL
4	NULL
days	NULL
were	NULL
negligible	NULL
(	NULL
less	NULL
than	NULL
20	NULL
U/ml	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
)	NULL
;	NULL
however	NULL
,	NULL
IFN	NULL
synthesis	NULL
(	NULL
about	NULL
200	NULL
U/ml	NULL
)	NULL
could	NULL
be	NULL
detected	NULL
in	NULL
these	NULL
cells	NULL
upon	NULL
prolonged	NULL
culti-vation	NULL
.	NULL

We	NULL
believed	NULL
that	NULL
this	NULL
increase	NULL
in	NULL
IFNAZ	NULL
synthesis	NULL
is	NULL
mediated	NULL
by	NULL
a	NULL
ISG15	NULL
element	NULL
present	NULL
in	NULL
our	NULL
construct	NULL
that	NULL
is	NULL
activated	NULL
by	NULL
constitutively	NULL
produced	NULL
IFNA	NULL
accumulating	NULL
in	NULL
these	NULL
cells	NULL
(	NULL
46	NULL
)	NULL
.	NULL

IFNAZ	NULL
synthesis	NULL
was	NULL
,	NULL
however	NULL
,	NULL
greatly	NULL
enhanced	NULL
in	NULL
infected	NULL
cells	NULL
with	NULL
the	NULL
highest	NULL
levels	NULL
at	NULL
10	NULL
days	NULL
postinfection	NULL
when	NULL
HIV-1	NULL
replication	NULL
in	NULL
both	NULL
Jurkat	NULL
and	NULL
JISG3-A	NULL
cells	NULL
reached	NULL
the	NULL
maximal	NULL
levels	NULL
;	NULL
IFNAZ	NULL
synthesis	NULL
stayed	NULL
elevated	NULL
in	NULL
infected	NULL
cells	NULL
throughout	NULL
the	NULL
whole	NULL
experi-ment	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
IFNA	NULL
produced	NULL
in	NULL
the	NULL
JISG3-A	NULL
clone	NULL
were	NULL
affected	NULL
by	NULL
the	NULL
multiplicity	NULL
of	NULL
HIV-1	NULL
infection	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
;	NULL
however	NULL
,	NULL
the	NULL
increase	NULL
was	NULL
not	NULL
linear	NULL
.	NULL

A	NULL
20-fold	NULL
increase	NULL
in	NULL
the	NULL
multiplicity	NULL
of	NULL
HIV-1	NULL
infection	NULL
increased	NULL
the	NULL
levels	NULL
of	NULL
IFN	NULL
in	NULL
the	NULL
medium	NULL
by	NULL
only	NULL
about	NULL
3-fold	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
IFNA2Z	NULL
synthesis	NULL
can	NULL
be	NULL
transactivated	NULL
in	NULL
HIV-1-infected	NULL
cells	NULL
even	NULL
when	NULL
the	NULL
levels	NULL
of	NULL
replicative	NULL
virus	NULL
are	NULL
very	NULL
low	NULL
.	NULL

The	NULL
inhibition	NULL
of	NULL
HIV-1	NULL
replication	NULL
in	NULL
JISG3-A	NULL
cells	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
an	NULL
increase	NULL
in	NULL
virus	NULL
multiplicity	NULL
in	NULL
the	NULL
range	NULL
of	NULL
MOI	NULL
Vou	NULL
.	NULL

69	NULL
,	NULL
1995	NULL
A	NULL
.	NULL

50000	NULL
4	NULL
OJISG3-A	NULL
a-	NULL
&	NULL
JURKAT	NULL
3	NULL
40000	NULL
+	NULL
&	NULL
wo	NULL
E	NULL
30000	NULL
+	NULL
a	NULL
.	NULL

0	NULL
€	NULL
20000	NULL
+	NULL
.	NULL

>	NULL
6	NULL
a	NULL
i	NULL
10000	NULL
,	NULL
Cl=	NULL
,	NULL
1	NULL
2	NULL
4	NULL
6	NULL
8	NULL
10	NULL
Days	NULL
after	NULL
infection	NULL
B	NULL
.	NULL

2°°°	NULL
T	NULL
quisosa	NULL
M	NULL
JISG3-A	NULL
/	NULL
HIV-1	NULL
1500	NULL
IFN	NULL
{	NULL
units	NULL
/	NULL
ml	NULL
)	NULL
3	NULL
f=3	NULL
©	NULL
on	NULL
o	NULL
-	NULL
]	NULL
&	NULL
|	NULL
_____OL	NULL
OL	NULL
2	NULL
10	NULL
12	NULL
14	NULL
Days	NULL
after	NULL
infection	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

Inhibition	NULL
of	NULL
HIV-1	NULL
replication	NULL
in	NULL
Jurkat	NULL
cells	NULL
transduced	NULL
with	NULL
Tat-inducible	NULL
IFNA2	NULL
gene	NULL
.	NULL

Jurkat	NULL
cells	NULL
and	NULL
Jurkat	NULL
clone	NULL
(	NULL
JISG3-A	NULL
)	NULL
containing	NULL
integrated	NULL
recombinant	NULL
plasmid	NULL
(	NULL
vector	NULL
IV	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
were	NULL
infected	NULL
with	NULL
HIV-1	NULL
(	NULL
pLN4-3	NULL
variant	NULL
)	NULL
at	NULL
a	NULL
MOI	NULL
of	NULL
0.01	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Medium	NULL
from	NULL
infected	NULL
cells	NULL
was	NULL
collected	NULL
every	NULL
second	NULL
day	NULL
and	NULL
analyzed	NULL
for	NULL
the	NULL
presence	NULL
of	NULL
HIV-1	NULL
by	NULL
the	NULL
RT	NULL
assay	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

(	NULL
B	NULL
)	NULL
The	NULL
levels	NULL
of	NULL
biological	NULL
active	NULL
IFNA2	NULL
protein	NULL
were	NULL
analyzed	NULL
in	NULL
both	NULL
infected	NULL
and	NULL
uninfected	NULL
JISG3-A	NULL
cells	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

0.025	NULL
to	NULL
0.05	NULL
.	NULL

Replication	NULL
of	NULL
HIV-1	NULL
in	NULL
Jurkat	NULL
cells	NULL
transfected	NULL
with	NULL
(	NULL
-83	NULL
)	NULL
LTR-IFNA2Z	NULL
(	NULL
JLTRS	NULL
)	NULL
was	NULL
not	NULL
tested	NULL
,	NULL
since	NULL
in	NULL
these	NULL
cells	NULL
IFN	NULL
synthesis	NULL
was	NULL
not	NULL
significantly	NULL
transactivated	NULL
by	NULL
Tat	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Replication	NULL
of	NULL
HIV-1	NULL
was	NULL
further	NULL
examined	NULL
in	NULL
two	NULL
clones	NULL
of	NULL
U937	NULL
cells	NULL
,	NULL
ULTRS-14	NULL
and	NULL
UISG3-8	NULL
,	NULL
containing	NULL
integrated	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR-IFNAZ	NULL
(	NULL
construct	NULL
I	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
and	NULL
ISG15-HIV-1	NULL
LTR-IFNAZ	NULL
(	NULL
construct	NULL
IV	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

In	NULL
both	NULL
of	NULL
these	NULL
clones	NULL
,	NULL
synthesis	NULL
of	NULL
IFNAZ	NULL
was	NULL
greatly	NULL
enhanced	NULL
upon	NULL
transfection	NULL
with	NULL
Tat-expressing	NULL
plasmid	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

9A	NULL
,	NULL
U937	NULL
cells	NULL
were	NULL
permissive	NULL
to	NULL
HIV-1	NULL
infection	NULL
,	NULL
with	NULL
maximal	NULL
virus	NULL
yield	NULL
obtained	NULL
about	NULL
17	NULL
days	NULL
postinfection	NULL
;	NULL
at	NULL
later	NULL
times	NULL
,	NULL
virus	NULL
production	NULL
decreased	NULL
because	NULL
of	NULL
the	NULL
cytopathic	NULL
effect	NULL
of	NULL
HIV-1	NULL
,	NULL
and	NULL
by	NULL
21	NULL
days	NULL
TABLE	NULL
3	NULL
.	NULL

Effect	NULL
of	NULL
multiplicity	NULL
of	NULL
HIV-1	NULL
infection	NULL
on	NULL
IFNA	NULL
production	NULL
in	NULL
JISG3-A	NULL
cells	NULL
``	NULL
IFN	NULL
level	NULL
(	NULL
U/ml	NULL
!	NULL
)	NULL

at	NULL
the	NULL
following	NULL
day	NULL
postinfection	NULL
:	NULL
Hiv	NULL
1	NULL
Mol	NULL
6	NULL
8	NULL
11	NULL
0.0025	NULL
45	NULL
65	NULL
ND	NULL
``	NULL
0.01	NULL
55	NULL
150	NULL
1,800	NULL
0.04	NULL
65	NULL
175	NULL
2,080	NULL
``	NULL
JISG3-A	NULL
cells	NULL
were	NULL
infected	NULL
with	NULL
HIV-1	NULL
at	NULL
the	NULL
indicated	NULL
MOIs	NULL
,	NULL
and	NULL
IFNA	NULL
levels	NULL
in	NULL
the	NULL
culture	NULL
medium	NULL
were	NULL
analyzed	NULL
at	NULL
6	NULL
,	NULL
8	NULL
,	NULL
and	NULL
11	NULL
days	NULL
postinfection	NULL
.	NULL

*	NULL
ND	NULL
,	NULL
not	NULL
determined	NULL
.	NULL

SELECTIVE	NULL
EXPRESSION	NULL
OF	NULL
A	NULL
TRANSDUCED	NULL
IFN	NULL
GENE	NULL
117	NULL
postinfection	NULL
,	NULL
more	NULL
than	NULL
70	NULL
%	NULL
of	NULL
cells	NULL
were	NULL
dead	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
HIV-1	NULL
replication	NULL
was	NULL
significantly	NULL
suppressed	NULL
in	NULL
the	NULL
ULTRS-14	NULL
clone	NULL
,	NULL
with	NULL
only	NULL
minimal	NULL
virus	NULL
replication	NULL
at	NULL
21	NULL
days	NULL
postinfection	NULL
and	NULL
no	NULL
detectable	NULL
cytopathic	NULL
effect	NULL
;	NULL
the	NULL
experiment	NULL
has	NULL
been	NULL
carried	NULL
for	NULL
40	NULL
days	NULL
without	NULL
detection	NULL
of	NULL
any	NULL
cytopathic	NULL
effect	NULL
and	NULL
significant	NULL
escape	NULL
of	NULL
HIV-1	NULL
from	NULL
the	NULL
IFNA2-mediated	NULL
inhibition	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
second	NULL
clone	NULL
tested	NULL
,	NULL
UISG3-8	NULL
,	NULL
was	NULL
virtually	NULL
nonpermissive	NULL
to	NULL
HIV-1	NULL
infection	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
there	NULL
is	NULL
a	NULL
direct	NULL
correlation	NULL
between	NULL
the	NULL
levels	NULL
of	NULL
synthesized	NULL
IFNAZ	NULL
in	NULL
the	NULL
infected	NULL
cells	NULL
and	NULL
inhibition	NULL
of	NULL
HIV-1	NULL
replication	NULL
,	NULL
we	NULL
measured	NULL
IFN	NULL
synthesis	NULL
in	NULL
these	NULL
two	NULL
clones	NULL
before	NULL
and	NULL
after	NULL
HIV-1	NULL
infection	NULL
.	NULL

ULTRS-14	NULL
clone	NULL
produced	NULL
relatively	NULL
high	NULL
levels	NULL
of	NULL
IFN	NULL
constitutively	NULL
(	NULL
700	NULL
to	NULL
1,000	NULL
U/ml	NULL
)	NULL
,	NULL
while	NULL
in	NULL
UISG3-8	NULL
cells	NULL
constitutive	NULL
IFN	NULL
synthesis	NULL
was	NULL
very	NULL
low	NULL
(	NULL
25	NULL
to	NULL
100	NULL
U/ml	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

9C	NULL
)	NULL
.	NULL

The	NULL
small	NULL
fluctuation	NULL
in	NULL
IFNAZ	NULL
levels	NULL
seen	NULL
during	NULL
the	NULL
cultivation	NULL
of	NULL
these	NULL
cells	NULL
represents	NULL
the	NULL
variability	NULL
in	NULL
a	NULL
biological	NULL
assay	NULL
.	NULL

A	NULL
marked	NULL
increase	NULL
in	NULL
IFNAZ	NULL
production	NULL
was	NULL
observed	NULL
upon	NULL
HIV-1	NULL
infection	NULL
in	NULL
ULTRS-14	NULL
clone	NULL
;	NULL
the	NULL
maximal	NULL
enhancement	NULL
(	NULL
fivefold	NULL
)	NULL
of	NULL
IFN	NULL
synthesis	NULL
was	NULL
seen	NULL
at	NULL
17	NULL
days	NULL
postinfection	NULL
,	NULL
which	NULL
coincided	NULL
with	NULL
the	NULL
maximal	NULL
virus	NULL
produc-tion	NULL
.	NULL

Although	NULL
the	NULL
enhancement	NULL
in	NULL
IFNAZ	NULL
synthesis	NULL
was	NULL
also	NULL
seen	NULL
in	NULL
UISG3-8	NULL
cells	NULL
,	NULL
the	NULL
relative	NULL
levels	NULL
were	NULL
lower	NULL
than	NULL
in	NULL
ULTRS-14	NULL
cells	NULL
,	NULL
and	NULL
maximal	NULL
enhancement	NULL
(	NULL
fourfold	NULL
)	NULL
was	NULL
observed	NULL
at	NULL
14	NULL
days	NULL
postinfection	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
difference	NULL
in	NULL
the	NULL
degree	NULL
of	NULL
inhibition	NULL
of	NULL
HIV-1	NULL
replication	NULL
between	NULL
these	NULL
two	NULL
clones	NULL
is	NULL
not	NULL
directly	NULL
related	NULL
to	NULL
the	NULL
levels	NULL
of	NULL
IFNAZ	NULL
produced	NULL
in	NULL
these	NULL
cells	NULL
,	NULL
and	NULL
additional	NULL
factors	NULL
may	NULL
have	NULL
played	NULL
a	NULL
role	NULL
in	NULL
the	NULL
resistance	NULL
of	NULL
the	NULL
UISG3-8	NULL
clone	NULL
.	NULL

Interestingly	NULL
,	NULL
IFNA2	NULL
synthesis	NULL
in	NULL
the	NULL
HIV-1-infected	NULL
cells	NULL
shows	NULL
periodicity	NULL
that	NULL
may	NULL
be	NULL
directly	NULL
related	NULL
to	NULL
the	NULL
levels	NULL
of	NULL
replicating	NULL
virus	NULL
and	NULL
Tat	NULL
protein	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

Since	NULL
we	NULL
could	NULL
detect	NULL
low	NULL
levels	NULL
of	NULL
HIV-1	NULL
replication	NULL
at	NULL
later	NULL
times	NULL
(	NULL
21	NULL
days	NULL
)	NULL
postinfection	NULL
in	NULL
ULTRS-14	NULL
cells	NULL
,	NULL
we	NULL
were	NULL
interested	NULL
to	NULL
determine	NULL
whether	NULL
this	NULL
virus	NULL
represents	NULL
an	NULL
IFNA-resistant	NULL
variant	NULL
.	NULL

We	NULL
,	NULL
therefore	NULL
,	NULL
compared	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
HIV-1	NULL
isolate	NULL
from	NULL
the	NULL
ULTRS-14	NULL
clone	NULL
to	NULL
replicate	NULL
in	NULL
U937	NULL
cells	NULL
and	NULL
the	NULL
ULTRS5-14	NULL
clone	NULL
.	NULL

The	NULL
results	NULL
in	NULL
Fig	NULL
.	NULL

10	NULL
show	NULL
that	NULL
while	NULL
this	NULL
HIV-1	NULL
isolate	NULL
replicated	NULL
effectively	NULL
in	NULL
U937	NULL
cells	NULL
,	NULL
its	NULL
replication	NULL
was	NULL
limited	NULL
in	NULL
the	NULL
ULTR-14	NULL
clone	NULL
,	NULL
suggesting	NULL
that	NULL
under	NULL
conditions	NULL
tested	NULL
,	NULL
this	NULL
virus	NULL
is	NULL
still	NULL
sensitive	NULL
to	NULL
the	NULL
IFNA	NULL
effect	NULL
.	NULL

DISCUSSION	NULL
In	NULL
a	NULL
previous	NULL
study	NULL
(	NULL
4	NULL
)	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
Tat	NULL
and	NULL
HIV-1	NULL
infection	NULL
induced	NULL
synthesis	NULL
of	NULL
IFN	NULL
encoded	NULL
by	NULL
a	NULL
transduced	NULL
LTR-IFNAZ	NULL
hybrid	NULL
gene	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
(	NULL
4	NULL
)	NULL
and	NULL
that	NULL
T	NULL
cells	NULL
containing	NULL
the	NULL
transactivable	NULL
IFNAZ	NULL
gene	NULL
were	NULL
nonpermissive	NULL
to	NULL
HIV-1	NULL
replication	NULL
.	NULL

However	NULL
,	NULL
HIV-1	NULL
LTR	NULL
can	NULL
be	NULL
activated	NULL
not	NULL
only	NULL
by	NULL
Tat	NULL
but	NULL
also	NULL
by	NULL
stimuli	NULL
that	NULL
increase	NULL
binding	NULL
of	NULL
the	NULL
NF-kB	NULL
heterodimer	NULL
to	NULL
the	NULL
enhancer	NULL
elements	NULL
of	NULL
HIV-1	NULL
LTR	NULL
;	NULL
this	NULL
mechanism	NULL
was	NULL
shown	NULL
to	NULL
play	NULL
a	NULL
major	NULL
role	NULL
in	NULL
TNF-	NULL
«	NULL
-mediated	NULL
activation	NULL
of	NULL
the	NULL
latent	NULL
HIV-1	NULL
provirus	NULL
and	NULL
its	NULL
Tat-defective	NULL
variant	NULL
(	NULL
43	NULL
,	NULL
60	NULL
)	NULL
.	NULL

Since	NULL
synthesis	NULL
of	NULL
TNF-a	NULL
can	NULL
be	NULL
detected	NULL
in	NULL
AIDS	NULL
patients	NULL
,	NULL
expression	NULL
by	NULL
the	NULL
transduced	NULL
HIV-1	NULL
LTR-IFNA	NULL
gene	NULL
in	NULL
vivo	NULL
would	NULL
not	NULL
be	NULL
limited	NULL
to	NULL
HIV-1-infected	NULL
cells	NULL
.	NULL

It	NULL
was	NULL
shown	NULL
that	NULL
the	NULL
xB	NULL
motifs	NULL
were	NULL
not	NULL
involved	NULL
in	NULL
Tat-mediated	NULL
activation	NULL
of	NULL
HIV-1	NULL
LTR	NULL
(	NULL
36	NULL
,	NULL
56	NULL
)	NULL
;	NULL
therefore	NULL
,	NULL
we	NULL
reasoned	NULL
that	NULL
deletion	NULL
of	NULL
these	NULL
two	NULL
elements	NULL
should	NULL
minimize	NULL
the	NULL
induction	NULL
of	NULL
HIV-1	NULL
LTR	NULL
by	NULL
cytokines	NULL
or	NULL
by	NULL
heterologous	NULL
viral	NULL
infection	NULL
,	NULL
both	NULL
of	NULL
which	NULL
are	NULL
mediated	NULL
by	NULL
NF-kB	NULL
(	NULL
43	NULL
,	NULL
60	NULL
,	NULL
61	NULL
)	NULL
,	NULL
without	NULL
affecting	NULL
Tat	NULL
transactivation	NULL
.	NULL

Surprisingly	NULL
,	NULL
we	NULL
found	NULL
that	NULL
in	NULL
cells	NULL
permissive	NULL
to	NULL
HIV-1	NULL
infection	NULL
,	NULL
HIV-1	NULL
LTR	NULL
in	NULL
which	NULL
the	NULL
xB	NULL
motifs	NULL
were	NULL
deleted	NULL
was	NULL
not	NULL
efficiently	NULL
transactivated	NULL
by	NULL
Tat	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

Since	NULL
in	NULL
most	NULL
118	NULL
SU	NULL
ET	NULL
AL	NULL
.	NULL

J	NULL
.	NULL

A	NULL
.	NULL

50000	NULL
H	NULL
U937	NULL
C	NULL
ULTRS-14	NULL
40000	NULL
+	NULL
quisG3-8	NULL
3	NULL
2	NULL
30000	NULL
+	NULL
[	NULL
=	NULL
Q	NULL
°	NULL
20000	NULL
+	NULL
'	NULL
_	NULL
[	NULL
+4	NULL
10000	NULL
+	NULL
0	NULL
|-	NULL
sem	NULL
4	NULL
+	NULL
+	NULL
:	NULL
4	NULL
7	NULL
12	NULL
14	NULL
17	NULL
Days	NULL
after	NULL
infection	NULL
B	NULL
.	NULL

-	NULL
350990	NULL
7+	NULL
G	NULL
uLTRS-14	NULL
/	NULL
HIV	NULL
2500	NULL
7	NULL
2000	NULL
1500	NULL
7	NULL
IFN	NULL
(	NULL
units	NULL
/	NULL
ml	NULL
)	NULL
1000	NULL
500	NULL
+	NULL
1	NULL
24	NULL
-	NULL
27	NULL
-	NULL
31	NULL
14	NULL
17	NULL
19	NULL
_	NULL
2	NULL
Days	NULL
after	NULL
infection	NULL
C.	NULL
OULTRS-14	NULL
AUuIsG3-8	NULL
t	NULL
O	NULL
O	NULL
O	NULL
2000	NULL
1000	NULL
IFN	NULL
(	NULL
units	NULL
/	NULL
ml	NULL
)	NULL
Days	NULL
after	NULL
infection	NULL
FIG	NULL
.	NULL

9	NULL
.	NULL

Inhibition	NULL
of	NULL
HIV-1	NULL
replication	NULL
in	NULL
U937	NULL
cells	NULL
containing	NULL
the	NULL
Tat-transactivable	NULL
IFNA2	NULL
gene	NULL
.	NULL

U937	NULL
cells	NULL
containing	NULL
integrated	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR-IFNA2	NULL
plasmid	NULL
(	NULL
vector	NULL
I	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
and	NULL
ISG15-HIV-1	NULL
LTR-IFNA2	NULL
plasmid	NULL
(	NULL
vector	NULL
IV	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
as	NULL
well	NULL
as	NULL
the	NULL
parental	NULL
U937	NULL
cell	NULL
line	NULL
were	NULL
infected	NULL
with	NULL
HIV-1	NULL
(	NULL
pLN4-3	NULL
)	NULL
at	NULL
a	NULL
MOI	NULL
of	NULL
0.01	NULL
,	NULL
and	NULL
the	NULL
levels	NULL
of	NULL
the	NULL
HIV-1	NULL
virions	NULL
(	NULL
A	NULL
)	NULL
and	NULL
biological	NULL
active	NULL
IFNA	NULL
protein	NULL
(	NULL
B	NULL
)	NULL
in	NULL
the	NULL
medium	NULL
of	NULL
infected	NULL
cells	NULL
were	NULL
determined	NULL
at	NULL
different	NULL
times	NULL
postinfection	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
IFNA2	NULL
in	NULL
the	NULL
medium	NULL
of	NULL
uninfected	NULL
cells	NULL
(	NULL
C	NULL
)	NULL
were	NULL
analyzed	NULL
for	NULL
comparison	NULL
.	NULL

Vou	NULL
.	NULL

69	NULL
,	NULL
1995	NULL
30000	NULL
m	NULL
U937	NULL
25000	NULL
O	NULL
ULTRS-14	NULL
20000	NULL
15000	NULL
10000	NULL
RT	NULL
{	NULL
cpm	NULL
/	NULL
10	NULL
ul	NULL
}	NULL
5000	NULL
3	NULL
6	NULL
9	NULL
11	NULL
14	NULL
17	NULL
20	NULL
25	NULL
Days	NULL
after	NULL
infection	NULL
FIG	NULL
.	NULL

10	NULL
.	NULL

HIV-1	NULL
replicating	NULL
in	NULL
ULTR5-14	NULL
cells	NULL
is	NULL
not	NULL
an	NULL
IFNA-insensitive	NULL
variant	NULL
.	NULL

HIV-1	NULL
isolate	NULL
from	NULL
ULTRS5-14	NULL
cells	NULL
at	NULL
21	NULL
days	NULL
postinfection	NULL
(	NULL
MOI	NULL
of	NULL
0.01	NULL
)	NULL
was	NULL
used	NULL
to	NULL
infect	NULL
U937	NULL
and	NULL
ULTR5-14	NULL
cells	NULL
,	NULL
and	NULL
viral	NULL
replication	NULL
of	NULL
this	NULL
variant	NULL
was	NULL
analyzed	NULL
by	NULL
measuring	NULL
the	NULL
levels	NULL
of	NULL
RT	NULL
in	NULL
the	NULL
medium	NULL
of	NULL
infected	NULL
cells	NULL
.	NULL

cells	NULL
classical	NULL
NF-KB	NULL
is	NULL
present	NULL
in	NULL
an	NULL
inactive	NULL
form	NULL
,	NULL
it	NULL
is	NULL
unlikely	NULL
that	NULL
this	NULL
factor	NULL
alone	NULL
plays	NULL
an	NULL
important	NULL
role	NULL
in	NULL
Tat-mediated	NULL
induction	NULL
of	NULL
HIV-1	NULL
LTR	NULL
,	NULL
unless	NULL
activated	NULL
during	NULL
the	NULL
course	NULL
of	NULL
Tat	NULL
synthesis	NULL
.	NULL

However	NULL
,	NULL
recent	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
Tat	NULL
protein	NULL
is	NULL
unable	NULL
to	NULL
enhance	NULL
expression	NULL
of	NULL
the	NULL
p105	NULL
gene	NULL
,	NULL
which	NULL
encodes	NULL
the	NULL
p105	NULL
precursor	NULL
of	NULL
the	NULL
p50	NULL
subunit	NULL
of	NULL
NF-kB	NULL
in	NULL
U937	NULL
cells	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
we	NULL
can	NULL
only	NULL
speculate	NULL
that	NULL
some	NULL
other	NULL
cellular	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
binds	NULL
to	NULL
the	NULL
xB	NULL
motifs	NULL
of	NULL
LTR	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
monocytes	NULL
and	NULL
cooperates	NULL
with	NULL
Tat	NULL
to	NULL
enhance	NULL
transactivation	NULL
.	NULL

Since	NULL
deletion	NULL
of	NULL
the	NULL
kB	NULL
motifs	NULL
resulted	NULL
in	NULL
inefficient	NULL
transactivation	NULL
of	NULL
LTR	NULL
by	NULL
the	NULL
Tat	NULL
protein	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
feasibility	NULL
of	NULL
increasing	NULL
IFNA	NULL
synthesis	NULL
through	NULL
enhancer	NULL
activity	NULL
and/or	NULL
a	NULL
possible	NULL
feedback	NULL
augmentation	NULL
by	NULL
the	NULL
IFN-induced	NULL
cellular	NULL
factor	NULL
ISGF-3	NULL
(	NULL
30	NULL
,	NULL
51	NULL
)	NULL
and	NULL
inserted	NULL
a	NULL
DNA	NULL
fragment	NULL
from	NULL
the	NULL
ISG15	NULL
promoter	NULL
region	NULL
,	NULL
containing	NULL
an	NULL
ISRE	NULL
,	NULL
upstream	NULL
of	NULL
HIV-1	NULL
LTR	NULL
with	NULL
deleted	NULL
kB	NULL
motifs	NULL
.	NULL

Although	NULL
it	NULL
had	NULL
been	NULL
shown	NULL
that	NULL
the	NULL
ISRE	NULL
of	NULL
the	NULL
ISG15	NULL
promoter	NULL
region	NULL
is	NULL
sufficient	NULL
for	NULL
transcriptional	NULL
induction	NULL
by	NULL
IFNA	NULL
(	NULL
31	NULL
)	NULL
,	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
monocytes	NULL
,	NULL
the	NULL
natural	NULL
ISG15	NULL
promoter	NULL
was	NULL
induced	NULL
more	NULL
efficiently	NULL
by	NULL
IFNAZ	NULL
than	NULL
the	NULL
three	NULL
copies	NULL
of	NULL
ISREs	NULL
,	NULL
suggesting	NULL
that	NULL
additional	NULL
cis-acting	NULL
sequences	NULL
in	NULL
the	NULL
ISG15	NULL
promoter	NULL
may	NULL
contribute	NULL
to	NULL
its	NULL
response	NULL
to	NULL
IFNA	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
ISG15	NULL
in	NULL
ISG15	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
significantly	NULL
increased	NULL
Tat	NULL
activation	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
constitutively	NULL
present	NULL
,	NULL
trans-acting	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
(	NULL
possibly	NULL
ISGF-2	NULL
[	NULL
31	NULL
]	NULL
)	NULL
bound	NULL
to	NULL
the	NULL
ISRE	NULL
enhancer	NULL
(	NULL
s	NULL
)	NULL
can	NULL
cooperate	NULL
with	NULL
Tat	NULL
.	NULL

In	NULL
T	NULL
cells	NULL
,	NULL
this	NULL
cooperation	NULL
seems	NULL
to	NULL
be	NULL
less	NULL
efficient	NULL
than	NULL
that	NULL
between	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Tat	NULL
,	NULL
which	NULL
is	NULL
more	NULL
than	NULL
additive	NULL
;	NULL
activation	NULL
of	NULL
wild-type	NULL
HIV-1	NULL
LTR	NULL
by	NULL
Tat	NULL
was	NULL
10	NULL
times	NULL
higher	NULL
than	NULL
that	NULL
of	NULL
ISG15	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
U937	NULL
cells	NULL
,	NULL
Tat-mediated	NULL
transactivation	NULL
of	NULL
ISG15	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
was	NULL
more	NULL
efficient	NULL
than	NULL
that	NULL
of	NULL
HIV-1	NULL
LTR	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

This	NULL
difference	NULL
in	NULL
the	NULL
Tat-mediated	NULL
effect	NULL
between	NULL
monocytes	NULL
and	NULL
T	NULL
cells	NULL
may	NULL
be	NULL
due	NULL
to	NULL
the	NULL
difference	NULL
in	NULL
constitutive	NULL
levels	NULL
of	NULL
the	NULL
trans-acting	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
interacting	NULL
with	NULL
the	NULL
ISG15	NULL
enhancer	NULL
(	NULL
s	NULL
)	NULL
.	NULL

In	NULL
both	NULL
cell	NULL
types	NULL
,	NULL
activation	NULL
of	NULL
the	NULL
ISG15	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
by	NULL
Tat	NULL
was	NULL
not	NULL
significantly	NULL
altered	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
exogenous	NULL
IFN	NULL
,	NULL
suggesting	NULL
a	NULL
lack	NULL
of	NULL
synergistic	NULL
interaction	NULL
between	NULL
the	NULL
IFNA-induced	NULL
ISGF-3	NULL
complex	NULL
and	NULL
Tat	NULL
.	NULL

One	NULL
important	NULL
feature	NULL
of	NULL
this	NULL
chimeric	NULL
HIV-1	NULL
LTR	NULL
is	NULL
the	NULL
elimination	NULL
of	NULL
its	NULL
response	NULL
to	NULL
the	NULL
NF-kB	NULL
inducer	NULL
(	NULL
s	NULL
)	NULL
,	NULL
and	NULL
limitation	NULL
of	NULL
its	NULL
expression	NULL
to	NULL
Tat-expressing	NULL
cells	NULL
.	NULL

Whereas	NULL
the	NULL
inducibility	NULL
of	NULL
TNF-a	NULL
«	NULL
was	NULL
abolished	NULL
completely	NULL
,	NULL
the	NULL
response	NULL
SELECTIVE	NULL
EXPRESSION	NULL
OF	NULL
A	NULL
TRANSDUCED	NULL
IFN	NULL
GENE	NULL
119	NULL
to	NULL
PMA	NULL
was	NULL
merely	NULL
decreased	NULL
,	NULL
since	NULL
PMA	NULL
activates	NULL
HIV-1	NULL
LTR	NULL
not	NULL
only	NULL
through	NULL
NF-	NULL
«	NULL
B	NULL
but	NULL
through	NULL
other	NULL
cellular	NULL
factors	NULL
as	NULL
well	NULL
(	NULL
50	NULL
)	NULL
.	NULL

Since	NULL
PMA	NULL
is	NULL
not	NULL
a	NULL
physiological	NULL
inducer	NULL
,	NULL
it	NULL
should	NULL
not	NULL
play	NULL
a	NULL
major	NULL
role	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
this	NULL
chimeric	NULL
promoter	NULL
in	NULL
vivo	NULL
.	NULL

However	NULL
,	NULL
additional	NULL
testing	NULL
of	NULL
this	NULL
plasmid	NULL
is	NULL
needed	NULL
to	NULL
evaluate	NULL
its	NULL
response	NULL
to	NULL
extracellular	NULL
stimuli	NULL
in	NULL
vivo	NULL
.	NULL

The	NULL
feasibility	NULL
of	NULL
using	NULL
a	NULL
chimeric	NULL
HIV-1	NULL
LTR	NULL
to	NULL
direct	NULL
IFN	NULL
synthesis	NULL
from	NULL
a	NULL
transduced	NULL
IFN	NULL
gene	NULL
in	NULL
HIV-1-infected	NULL
cells	NULL
was	NULL
shown	NULL
in	NULL
both	NULL
T	NULL
cells	NULL
(	NULL
Jurkat	NULL
)	NULL
and	NULL
promonocytic	NULL
(	NULL
U937	NULL
)	NULL
cells	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
transiently	NULL
transfected	NULL
cells	NULL
,	NULL
expression	NULL
of	NULL
this	NULL
modified	NULL
HIV-1	NULL
LTR	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Tat	NULL
was	NULL
either	NULL
undetectable	NULL
(	NULL
Jurkat	NULL
cells	NULL
)	NULL
or	NULL
very	NULL
low	NULL
(	NULL
U937	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
low	NULL
levels	NULL
of	NULL
constitutive	NULL
IFNAZ	NULL
synthesis	NULL
(	NULL
about	NULL
50	NULL
U	NULL
)	NULL
were	NULL
observed	NULL
in	NULL
pools	NULL
of	NULL
monocytes	NULL
and	NULL
T	NULL
cells	NULL
containing	NULL
integrated	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
or	NULL
ISG15-HIV-1	NULL
LTR-IFNA2	NULL
plasmids	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
when	NULL
individual	NULL
clones	NULL
were	NULL
analyzed	NULL
,	NULL
a	NULL
majority	NULL
of	NULL
transduced	NULL
clones	NULL
produced	NULL
low	NULL
levels	NULL
of	NULL
IFNA	NULL
constitutively	NULL
(	NULL
5	NULL
to	NULL
50	NULL
U/ml	NULL
)	NULL
,	NULL
while	NULL
a	NULL
small	NULL
percentage	NULL
of	NULL
clones	NULL
synthesized	NULL
more	NULL
than	NULL
100	NULL
U	NULL
of	NULL
IFNAZ	NULL
per	NULL
ml	NULL
.	NULL

We	NULL
do	NULL
not	NULL
know	NULL
presently	NULL
whether	NULL
a	NULL
high	NULL
level	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
transduced	NULL
IFNAZ	NULL
gene	NULL
in	NULL
these	NULL
clones	NULL
is	NULL
a	NULL
consequence	NULL
of	NULL
the	NULL
presence	NULL
of	NULL
ISRE	NULL
in	NULL
the	NULL
hybrid	NULL
plasmid	NULL
or	NULL
reflects	NULL
a	NULL
multiple	NULL
integration	NULL
or	NULL
position	NULL
effect	NULL
leading	NULL
to	NULL
an	NULL
enhanced	NULL
transcriptional	NULL
activity	NULL
.	NULL

Our	NULL
data	NULL
,	NULL
however	NULL
,	NULL
indicate	NULL
that	NULL
the	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
is	NULL
not	NULL
completely	NULL
transcriptionally	NULL
inactive	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Tat	NULL
protein	NULL
;	NULL
the	NULL
high	NULL
specific	NULL
activity	NULL
of	NULL
IFNA	NULL
(	NULL
about	NULL
2.4	NULL
x	NULL
10°	NULL
U/mg	NULL
)	NULL
provides	NULL
a	NULL
detection	NULL
sensitivity	NULL
not	NULL
available	NULL
in	NULL
a	NULL
conventional	NULL
assay	NULL
(	NULL
measuring	NULL
the	NULL
levels	NULL
of	NULL
RNA	NULL
transcripts	NULL
)	NULL
.	NULL

While	NULL
replication	NULL
of	NULL
HIV-1	NULL
was	NULL
significantly	NULL
suppressed	NULL
in	NULL
transduced	NULL
cells	NULL
,	NULL
it	NULL
was	NULL
sufficient	NULL
to	NULL
stimulate	NULL
IFNA	NULL
synthesis	NULL
in	NULL
these	NULL
cells	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
only	NULL
very	NULL
low	NULL
levels	NULL
of	NULL
Tat	NULL
protein	NULL
are	NULL
needed	NULL
for	NULL
transactivation	NULL
of	NULL
a	NULL
transduced	NULL
IFNA	NULL
gene	NULL
.	NULL

Both	NULL
the	NULL
inhibition	NULL
of	NULL
HIV-1	NULL
replication	NULL
and	NULL
synthesis	NULL
of	NULL
IFNA	NULL
persisted	NULL
in	NULL
the	NULL
infected	NULL
cells	NULL
up	NULL
to	NULL
a	NULL
month	NULL
postinfection	NULL
.	NULL

Synthesized	NULL
IFNA	NULL
protected	NULL
the	NULL
infected	NULL
cultures	NULL
from	NULL
the	NULL
HIV-1-induced	NULL
cytopathic	NULL
changes	NULL
,	NULL
while	NULL
it	NULL
did	NULL
not	NULL
alter	NULL
the	NULL
growth	NULL
rate	NULL
of	NULL
transduced	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
constitutive	NULL
IFNA	NULL
synthesis	NULL
also	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
mitogenic	NULL
response	NULL
of	NULL
these	NULL
cells	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
their	NULL
abilities	NULL
to	NULL
express	NULL
IL-2	NULL
and	NULL
IL-Z2R	NULL
genes	NULL
upon	NULL
PHA	NULL
and	NULL
PMA	NULL
stimulation	NULL
.	NULL

Our	NULL
study	NULL
showed	NULL
,	NULL
however	NULL
,	NULL
that	NULL
should	NULL
the	NULL
transfer	NULL
of	NULL
IFNA	NULL
gene	NULL
be	NULL
used	NULL
in	NULL
clinical	NULL
studies	NULL
,	NULL
the	NULL
packaging	NULL
of	NULL
the	NULL
recombinant	NULL
retrovirus	NULL
vector	NULL
into	NULL
the	NULL
amphotropic	NULL
virus	NULL
pseudotype	NULL
has	NULL
to	NULL
be	NULL
optimized	NULL
.	NULL

The	NULL
yields	NULL
of	NULL
recombinant	NULL
virus	NULL
produced	NULL
by	NULL
a	NULL
majority	NULL
of	NULL
the	NULL
selected	NULL
clones	NULL
were	NULL
low	NULL
and	NULL
somewhat	NULL
indirectly	NULL
related	NULL
to	NULL
the	NULL
levels	NULL
of	NULL
IFNA	NULL
produced	NULL
in	NULL
transfected	NULL
clones	NULL
;	NULL
the	NULL
highest	NULL
virus	NULL
yield	NULL
was	NULL
obtained	NULL
from	NULL
cell	NULL
clones	NULL
that	NULL
produced	NULL
very	NULL
low	NULL
levels	NULL
of	NULL
IFNA	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
(	NULL
40	NULL
)	NULL
that	NULL
assembly	NULL
of	NULL
murine	NULL
retrovirus	NULL
is	NULL
inhibited	NULL
in	NULL
IFN-treated	NULL
cells	NULL
,	NULL
but	NULL
we	NULL
expected	NULL
that	NULL
the	NULL
low	NULL
levels	NULL
of	NULL
constitutively	NULL
produced	NULL
human	NULL
IFNA	NULL
in	NULL
the	NULL
murine	NULL
packaging	NULL
line	NULL
would	NULL
not	NULL
have	NULL
a	NULL
major	NULL
effect	NULL
on	NULL
the	NULL
assembly	NULL
of	NULL
the	NULL
recombinant	NULL
virus	NULL
.	NULL

Additional	NULL
studies	NULL
will	NULL
have	NULL
to	NULL
determine	NULL
whether	NULL
a	NULL
high	NULL
yield	NULL
of	NULL
recombinant	NULL
virus	NULL
could	NULL
be	NULL
obtained	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
anti-human	NULL
IFNA	NULL
antibodies	NULL
or	NULL
whether	NULL
other	NULL
viral	NULL
vectors	NULL
may	NULL
provide	NULL
an	NULL
alternative	NULL
,	NULL
more	NULL
effective	NULL
strategy	NULL
for	NULL
delivery	NULL
of	NULL
IFNA	NULL
genes	NULL
.	NULL

The	NULL
IFNA-mediated	NULL
inhibition	NULL
of	NULL
HIV-1	NULL
replication	NULL
shows	NULL
several	NULL
unique	NULL
features	NULL
compared	NULL
with	NULL
the	NULL
other	NULL
HIV-1	NULL
inhibitors	NULL
used	NULL
in	NULL
the	NULL
gene	NULL
therapy	NULL
approach	NULL
.	NULL

First	NULL
,	NULL
the	NULL
long-lasting	NULL
suppression	NULL
of	NULL
HIV-1	NULL
replication	NULL
in	NULL
cells	NULL
that	NULL
synthesize	NULL
IFNA2	NULL
in	NULL
an	NULL
autocrine	NULL
fashion	NULL
suggests	NULL
that	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
IFN-resistant	NULL
HIV-1	NULL
phenotype	NULL
is	NULL
not	NULL
acquired	NULL
as	NULL
easily	NULL
as	NULL
resistance	NULL
to	NULL
nucleoside	NULL
inhibitors	NULL
or	NULL
ribozymes	NULL
is	NULL
(	NULL
37	NULL
,	NULL
52	NULL
)	NULL
.	NULL

We	NULL
120	NULL
SU	NULL
ET	NULL
AL	NULL
.	NULL

have	NULL
previously	NULL
shown	NULL
that	NULL
in	NULL
a	NULL
single-step	NULL
cycle	NULL
infection	NULL
,	NULL
IFNA	NULL
inhibits	NULL
HIV-1	NULL
replication	NULL
on	NULL
a	NULL
preintegrational	NULL
step	NULL
at	NULL
the	NULL
level	NULL
of	NULL
provirus	NULL
formation	NULL
(	NULL
55	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
in	NULL
cells	NULL
transduced	NULL
with	NULL
the	NULL
transactivable	NULL
IFN	NULL
gene	NULL
,	NULL
there	NULL
was	NULL
marked	NULL
inhibition	NULL
of	NULL
provirus	NULL
integration	NULL
and	NULL
expression	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
inability	NULL
of	NULL
HIV-1	NULL
to	NULL
escape	NULL
IFNA-mediated	NULL
inhibition	NULL
easily	NULL
suggests	NULL
that	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
IFN-resistant	NULL
HIV-1	NULL
phenotype	NULL
may	NULL
involve	NULL
larger	NULL
changes	NULL
than	NULL
point	NULL
mutations	NULL
found	NULL
in	NULL
zidovudine	NULL
and	NULL
ribozyme-resistant	NULL
HIV-1	NULL
variants	NULL
(	NULL
37	NULL
,	NULL
52	NULL
)	NULL
.	NULL

Second	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
ribozymes	NULL
or	NULL
dominant	NULL
negative	NULL
mutants	NULL
that	NULL
have	NULL
been	NULL
used	NULL
for	NULL
intracel-lular	NULL
``	NULL
immunization	NULL
,	NULL
``	NULL
transduction	NULL
of	NULL
the	NULL
IFNAZ	NULL
gene	NULL
is	NULL
associated	NULL
with	NULL
the	NULL
amplification	NULL
effect	NULL
mediated	NULL
by	NULL
a	NULL
released	NULL
IFNA	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
IFNA	NULL
to	NULL
inhibit	NULL
HIV-1	NULL
replication	NULL
by	NULL
both	NULL
the	NULL
autocrine	NULL
and	NULL
paracrine	NULL
mechanisms	NULL
would	NULL
be	NULL
of	NULL
a	NULL
great	NULL
advantage	NULL
for	NULL
its	NULL
use	NULL
in	NULL
vivo	NULL
,	NULL
where	NULL
transduction	NULL
of	NULL
a	NULL
protective	NULL
gene	NULL
into	NULL
every	NULL
cell	NULL
is	NULL
not	NULL
easily	NULL
attainable	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
modified	NULL
ISG15-HIV-1	NULL
LTR	NULL
promoter	NULL
is	NULL
able	NULL
to	NULL
direct	NULL
high	NULL
levels	NULL
of	NULL
IFNA2	NULL
synthesis	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
and	NULL
monocytes	NULL
infected	NULL
with	NULL
HIV-1	NULL
.	NULL

Unlike	NULL
endogenous	NULL
IFNA	NULL
,	NULL
expression	NULL
of	NULL
the	NULL
transduced	NULL
ISG15-HIV-1	NULL
LTR-IFNA	NULL
gene	NULL
is	NULL
induced	NULL
by	NULL
HIV-1	NULL
infection	NULL
,	NULL
and	NULL
its	NULL
induction	NULL
is	NULL
further	NULL
enhanced	NULL
by	NULL
IFNA	NULL
;	NULL
in	NULL
contrast	NULL
to	NULL
the	NULL
natural	NULL
HIV-1	NULL
LTR	NULL
,	NULL
the	NULL
chimeric	NULL
HIV-1	NULL
LTR	NULL
is	NULL
not	NULL
stimulated	NULL
by	NULL
NF-	NULL
«	NULL
B-specific	NULL
activators	NULL
such	NULL
as	NULL
TNF-	NULL
«	NULL
.	NULL

It	NULL
will	NULL
be	NULL
of	NULL
interest	NULL
to	NULL
examine	NULL
whether	NULL
primary	NULL
PBMC	NULL
or	NULL
macrophages	NULL
containing	NULL
the	NULL
transduced	NULL
ISG15-LTR-IFNAZ	NULL
hybrid	NULL
gene	NULL
are	NULL
resistant	NULL
to	NULL
HIV-1	NULL
infection	NULL
and	NULL
retain	NULL
their	NULL
immune	NULL
functions	NULL
.	NULL

These	NULL
experiments	NULL
are	NULL
currently	NULL
under	NULL
way	NULL
in	NULL
our	NULL
laboratory	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Public	NULL
Health	NULL
Service	NULL
grants	NULL
AI27297	NULL
and	NULL
AI26123	NULL
from	NULL
the	NULL
National	NULL
Institute	NULL
of	NULL
Allergy	NULL
and	NULL
Diseases	NULL
(	NULL
P.M.P	NULL
.	NULL
)	NULL

and	NULL
by	NULL
American	NULL
Foundation	NULL
for	NULL
AIDS	NULL
Research	NULL
grant	NULL
001684-13-RGR	NULL
(	NULL
P.M.P	NULL
.	NULL
)	NULL

.	NULL

We	NULL
thank	NULL
Nancy	NULL
Reich	NULL
for	NULL
the	NULL
gifts	NULL
of	NULL
pNcoISG15-EIB	NULL
and	NULL
ISG15-TK-3	NULL
plasmids	NULL
,	NULL
Christopher	NULL
D.	NULL
Southgate	NULL
and	NULL
Michael	NULL
R.	NULL
Green	NULL
for	NULL
(	NULL
-83	NULL
)	NULL
HIV-1	NULL
LTR	NULL
CAT	NULL
plasmids	NULL
,	NULL
Elizabeth	NULL
Jaffe	NULL
for	NULL
the	NULL
pcDHuIL-2	NULL
plasmid	NULL
,	NULL
and	NULL
Warren	NULL
Leonard	NULL
for	NULL
the	NULL
IL-2RfB	NULL
plasmid	NULL
.	NULL

We	NULL
further	NULL
thank	NULL
Merrill	NULL
Kellum	NULL
for	NULL
establishment	NULL
of	NULL
the	NULL
permanently	NULL
transfected	NULL
cell	NULL
lines	NULL
,	NULL
Deborah	NULL
Swanson	NULL
for	NULL
an	NULL
analysis	NULL
of	NULL
transfected	NULL
PA317	NULL
clones	NULL
,	NULL
Jaromir	NULL
Vlach	NULL
for	NULL
a	NULL
construction	NULL
of	NULL
the	NULL
IFNA	NULL
pLNL6	NULL
recombinant	NULL
vector	NULL
,	NULL
and	NULL
Pamela	NULL
Talalay	NULL
for	NULL
her	NULL
critical	NULL
review	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

We	NULL
thank	NULL
Barbara	NULL
Schneider	NULL
for	NULL
typing	NULL
and	NULL
formatting	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Baeuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1988	NULL
.	NULL

Activation	NULL
of	NULL
DNA-binding	NULL
activity	NULL
in	NULL
an	NULL
apparently	NULL
cytoplasmic	NULL
precursor	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
transcription	NULL
factor	NULL
.	NULL

Cell	NULL
53:211-217	NULL
.	NULL

2	NULL
.	NULL

Baeuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1989	NULL
.	NULL

A	NULL
65-kd	NULL
subunit	NULL
of	NULL
active	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
required	NULL
for	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
IxB	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

3:1689-1698	NULL
.	NULL

3	NULL
.	NULL

Ballard	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
E.	NULL
Bohnlein	NULL
,	NULL
J.	NULL
W.	NULL
Lowenthal	NULL
,	NULL
Y.	NULL
Wano	NULL
,	NULL
B.	NULL
R.	NULL
Franza	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1988	NULL
.	NULL

HTLV-I	NULL
Tax	NULL
induces	NULL
cellular	NULL
proteins	NULL
that	NULL
activate	NULL
the	NULL
xB	NULL
clement	NULL
in	NULL
the	NULL
IL-2	NULL
receptor	NULL
«	NULL
gene	NULL
.	NULL

Science	NULL
241:1652-1655	NULL
.	NULL

4	NULL
.	NULL

Bednarik	NULL
,	NULL
D.	NULL
P.	NULL
,	NULL
J.	NULL
D.	NULL
Mosca	NULL
,	NULL
N.	NULL
B.	NULL
K.	NULL
Raj	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Pitha	NULL
.	NULL

1989	NULL
.	NULL

Inhibition	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
replication	NULL
by	NULL
HIV-trans-activated	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:4958-4962	NULL
.	NULL

5	NULL
.	NULL

Bender	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
T.	NULL
D.	NULL
Palmer	NULL
,	NULL
R.	NULL
E.	NULL
Gelinas	NULL
,	NULL
and	NULL
A.	NULL
D.	NULL
Miller	NULL
.	NULL

1987	NULL
.	NULL

Evidence	NULL
that	NULL
the	NULL
packaging	NULL
signal	NULL
of	NULL
Moloney	NULL
murine	NULL
leukemia	NULL
virus	NULL
extends	NULL
into	NULL
the	NULL
gag	NULL
region	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

61:1639-1646	NULL
.	NULL

6	NULL
.	NULL

Bisat	NULL
,	NULL
F.	NULL
,	NULL
N.	NULL
B.	NULL
K.	NULL
Raj	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Pitha	NULL
.	NULL

1988	NULL
.	NULL

Differential	NULL
and	NULL
cell	NULL
type	NULL
specific	NULL
expression	NULL
of	NULL
murine	NULL
alpha-interferon	NULL
genes	NULL
is	NULL
regulated	NULL
on	NULL
the	NULL
transcriptional	NULL
level	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

16:6067-6083	NULL
.	NULL

7	NULL
.	NULL

Borden	NULL
,	NULL
E.	NULL
C.	NULL
,	NULL
and	NULL
L.	NULL
A	NULL
.	NULL

Ball	NULL
.	NULL

1989	NULL
.	NULL

Interferons	NULL
:	NULL
biochemical	NULL
,	NULL
cell	NULL
growth	NULL
inhibitory	NULL
and	NULL
immunological	NULL
effects	NULL
.	NULL

Prog	NULL
.	NULL

Hematol	NULL
.	NULL

12:299-339	NULL
.	NULL

8	NULL
.	NULL

Chirgwin	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
A.	NULL
E.	NULL
Przybyla	NULL
,	NULL
R.	NULL
J.	NULL
MacDonald	NULL
,	NULL
and	NULL
W.	NULL
J.	NULL
Rutter	NULL
.	NULL

1979	NULL
.	NULL

Isolation	NULL
of	NULL
biologically	NULL
active	NULL
ribonucleic	NULL
acid	NULL
from	NULL
sources	NULL
enriched	NULL
in	NULL
ribonuclease	NULL
.	NULL

Biochemistry	NULL
18:5294-5299	NULL
.	NULL

9	NULL
.	NULL

Chomezynski	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
N.	NULL
Sacchi	NULL
.	NULL

1987	NULL
.	NULL

Single-step	NULL
method	NULL
of	NULL
RNA	NULL
isolation	NULL
by	NULL
acid	NULL
guanidinium	NULL
thiocyanate-phenol-chloroform	NULL
extraction	NULL
.	NULL

Anal	NULL
.	NULL

Bio-chem	NULL
.	NULL

162:156-159	NULL
.	NULL

J.	NULL
ViroL	NULL
.	NULL

10	NULL
.	NULL

De	NULL
Wit	NULL
,	NULL
R.	NULL
,	NULL
J.	NULL
K.	NULL
Schatenkerk	NULL
,	NULL
C.	NULL
B.	NULL
Bouchler	NULL
,	NULL
P.	NULL
J.	NULL
Bakker	NULL
,	NULL
K.	NULL
H.	NULL
Veenhof	NULL
,	NULL
and	NULL
S.	NULL
A.	NULL
Danner	NULL
.	NULL

1988	NULL
.	NULL

Clinical	NULL
and	NULL
virological	NULL
effects	NULL
of	NULL
high-dose	NULL
recombinant	NULL
interferon-	NULL
«	NULL
in	NULL
disseminated	NULL
AIDS-related	NULL
Kaposi	NULL
's	NULL
sarcoma	NULL
.	NULL

Lancet	NULL
ii1214-1217	NULL
.	NULL

10a.Diaz	NULL
,	NULL
M.	NULL
O.	NULL
,	NULL
S.	NULL
Bohlander	NULL
,	NULL
and	NULL
G.	NULL
Allen	NULL
.	NULL

1993	NULL
.	NULL

Nomenclature	NULL
of	NULL
the	NULL
human	NULL
interferon	NULL
genes	NULL
.	NULL

J.	NULL
Interferon	NULL
Res	NULL
.	NULL

13:443-444	NULL
.	NULL

11	NULL
.	NULL

Dolei	NULL
,	NULL
A.	NULL
,	NULL
A.	NULL
Fattorossi	NULL
,	NULL
R.	NULL
D'Amelio	NULL
,	NULL
F.	NULL
Aiuti	NULL
,	NULL
and	NULL
F.	NULL
Dianzani	NULL
.	NULL

1986	NULL
.	NULL

Direct	NULL
and	NULL
cell-mediated	NULL
effects	NULL
of	NULL
interferon-	NULL
and	NULL
-y	NULL
on	NULL
cells	NULL
chronically	NULL
infected	NULL
with	NULL
HTLV-II	NULL
.	NULL

J.	NULL
Interferon	NULL
Res	NULL
.	NULL

6543-549	NULL
.	NULL

12	NULL
.	NULL

Dubh	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
W.	NULL
J.	NULL
Maury	NULL
,	NULL
T.	NULL
M.	NULL
Folks	NULL
,	NULL
A.	NULL
S.	NULL
Fauci	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rabson	NULL
.	NULL

1989	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
«	NULL
activates	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
through	NULL
induction	NULL
of	NULL
nuclear	NULL
factor	NULL
binding	NULL
to	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
sites	NULL
in	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:5974-5978	NULL
.	NULL

13	NULL
.	NULL

Dzierzak	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
T.	NULL
Papayannopoulou	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Mulligan	NULL
.	NULL

1988	NULL
.	NULL

Lincage-specific	NULL
expression	NULL
of	NULL
a	NULL
human	NULL
B-globin	NULL
gene	NULL
in	NULL
murine	NULL
bone	NULL
marrow	NULL
transplant	NULL
recipients	NULL
reconstituted	NULL
with	NULL
retrovirus-transduced	NULL
stem	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
331:35-41	NULL
.	NULL

14	NULL
.	NULL

Engelhardt	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
M.	NULL
J.	NULL
Kellum	NULL
,	NULL
F.	NULL
Bisat	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Pitha	NULL
.	NULL

1990	NULL
.	NULL

Retrovirus	NULL
vector-targeted	NULL
inducible	NULL
expression	NULL
of	NULL
human	NULL
B-interferon	NULL
gene	NULL
to	NULL
B-cells	NULL
.	NULL

Virology	NULL
178:419-428	NULL
.	NULL

15	NULL
.	NULL

Finter	NULL
,	NULL
N.	NULL
B	NULL
.	NULL

1969	NULL
.	NULL

Dyc	NULL
uptake	NULL
methods	NULL
for	NULL
assessing	NULL
viral	NULL
cytopathogenicity	NULL
and	NULL
their	NULL
application	NULL
to	NULL
interferon	NULL
assay	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

5:419-427	NULL
.	NULL

16	NULL
.	NULL

Friedman	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
S.	NULL
P.	NULL
Manley	NULL
,	NULL
M.	NULL
McMahon	NULL
,	NULL
I.	NULL
M.	NULL
Kerr	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Stark	NULL
,	NULL
1984	NULL
.	NULL

Transcriptional	NULL
and	NULL
post-transcriptional	NULL
regulation	NULL
of	NULL
interferon-induced	NULL
gene	NULL
expression	NULL
in	NULL
human	NULL
cells	NULL
.	NULL

Cell	NULL
38:745-755	NULL
.	NULL

17	NULL
.	NULL

Gendelman	NULL
,	NULL
H.	NULL
E.	NULL
,	NULL
L.	NULL
M.	NULL
Baca	NULL
,	NULL
J.	NULL
Turpin	NULL
,	NULL
D.	NULL
C.	NULL
Kalter	NULL
,	NULL
B.	NULL
Hansen	NULL
,	NULL
J.	NULL
M.	NULL
Orenstein	NULL
,	NULL
C.	NULL
W.	NULL
Dieffenbach	NULL
,	NULL
R.	NULL
M.	NULL
Friedman	NULL
,	NULL
and	NULL
M.	NULL
S.	NULL
Meltzer	NULL
.	NULL

1990	NULL
.	NULL

Regulation	NULL
of	NULL
HIV	NULL
replication	NULL
in	NULL
infected	NULL
monocytes	NULL
by	NULL
IFN-	NULL
«	NULL
mechanisms	NULL
for	NULL
viral	NULL
restriction	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

145:2669-2676	NULL
.	NULL

18	NULL
.	NULL

Gimble	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
E.	NULL
Dub	NULL
,	NULL
J.	NULL
M.	NULL
Ostrove	NULL
,	NULL
H.	NULL
E.	NULL
Gendelman	NULL
,	NULL
E.	NULL
E.	NULL
Max	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Rabson	NULL
.	NULL

1988	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
by	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
is	NULL
associated	NULL
with	NULL
induction	NULL
of	NULL
a	NULL
nuclear	NULL
factor	NULL
that	NULL
binds	NULL
to	NULL
the	NULL
NF-B/core	NULL
enhancer	NULL
sequences	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

62:4104-4112	NULL
.	NULL

19	NULL
.	NULL

Gorman	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
L.	NULL
F.	NULL
Moffat	NULL
,	NULL
and	NULL
B.	NULL
H.	NULL
Howard	NULL
.	NULL

1982	NULL
.	NULL

Recombinant	NULL
genomes	NULL
which	NULL
express	NULL
chloramphenicol	NULL
acetyltransferase	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

21044-1051	NULL
.	NULL

20	NULL
.	NULL

Griffin	NULL
,	NULL
G.	NULL
E.	NULL
,	NULL
K.	NULL
Leung	NULL
,	NULL
T.	NULL
M.	NULL
Folks	NULL
,	NULL
S.	NULL
Kunkel	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1989	NULL
.	NULL

Activation	NULL
of	NULL
HIV	NULL
gene	NULL
expression	NULL
during	NULL
monocyte	NULL
differentiation	NULL
by	NULL
induction	NULL
of	NULL
NF-xB	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
339:70-73	NULL
.	NULL

21	NULL
.	NULL

Hartshorn	NULL
,	NULL
K.	NULL
L.	NULL
,	NULL
D.	NULL
Neumeyer	NULL
,	NULL
M.	NULL
W.	NULL
Vogt	NULL
,	NULL
R.	NULL
T.	NULL
Schooley	NULL
,	NULL
and	NULL
M.	NULL
S.	NULL
Hirsch	NULL
.	NULL

1987	NULL
.	NULL

Activity	NULL
of	NULL
interferons	NULL
alpha	NULL
,	NULL
beta	NULL
,	NULL
and	NULL
gamma	NULL
against	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
replication	NULL
in	NULL
vitro	NULL
.	NULL

AIDS	NULL
Res	NULL
.	NULL

Hum	NULL
.	NULL

Retroviruses	NULL
3:125-133	NULL
.	NULL

22	NULL
.	NULL

Ho	NULL
,	NULL
D.	NULL
D.	NULL
,	NULL
T.	NULL
R.	NULL
Rota	NULL
,	NULL
J.	NULL
C.	NULL
Kaplan	NULL
,	NULL
K.	NULL
L.	NULL
Hartshorn	NULL
,	NULL
C.	NULL
A.	NULL
Andrews	NULL
,	NULL
R.	NULL
T.	NULL
Schooley	NULL
,	NULL
and	NULL
M.	NULL
S.	NULL
Hirsch	NULL
.	NULL

1985	NULL
.	NULL

Recombinant	NULL
human	NULL
interferon	NULL
alfa-A	NULL
suppresses	NULL
HTLV-III	NULL
replication	NULL
in	NULL
vitro	NULL
.	NULL

Lancet	NULL
i:602-604	NULL
.	NULL

23	NULL
.	NULL

Israel	NULL
,	NULL
N.	NULL
,	NULL
U.	NULL
Hazan	NULL
,	NULL
J.	NULL
Alcami	NULL
,	NULL
A.	NULL
Munier	NULL
,	NULL
F.	NULL
Arenzana-Seisdedos	NULL
,	NULL
F.	NULL
Bachelerie	NULL
,	NULL
A.	NULL
Israel	NULL
,	NULL
and	NULL
J.-L.	NULL
Virelizier	NULL
.	NULL

1989	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
stimulates	NULL
transcription	NULL
of	NULL
HIV-1	NULL
in	NULL
human	NULL
T	NULL
lymphocytes	NULL
,	NULL
independently	NULL
and	NULL
synergistically	NULL
with	NULL
mitogens	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

143:3956-3960	NULL
.	NULL

24	NULL
.	NULL

Kaufman	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
G.	NULL
Valandra	NULL
,	NULL
G.	NULL
Roderiquez	NULL
,	NULL
G.	NULL
Bushar	NULL
,	NULL
C.	NULL
Giri	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Norcross	NULL
.	NULL

1987	NULL
.	NULL

Phorbol	NULL
ester	NULL
enhances	NULL
human	NULL
immunodeficiency	NULL
virus-promoted	NULL
gene	NULL
expression	NULL
and	NULL
acts	NULL
on	NULL
a	NULL
repeated	NULL
10-base-pair	NULL
functional	NULL
enhancer	NULL
element	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

7:3759-3766	NULL
.	NULL

25	NULL
.	NULL

Kawakami	NULL
,	NULL
K.	NULL
,	NULL
C.	NULL
Scheidereit	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1988	NULL
.	NULL

Identification	NULL
and	NULL
purification	NULL
of	NULL
a	NULL
human	NULL
immunoglobulin-enhancer-binding	NULL
protein	NULL
(	NULL
NF-xB	NULL
)	NULL
that	NULL
activates	NULL
transcription	NULL
from	NULL
a	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
promoter	NULL
in	NULL
vitro	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:4700-4704	NULL
.	NULL

26	NULL
.	NULL

Kornbluth	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
P.	NULL
S.	NULL
Ob	NULL
,	NULL
J.	NULL
R.	NULL
Munis	NULL
,	NULL
P.	NULL
H.	NULL
Cleveland	NULL
,	NULL
and	NULL
D.	NULL
D.	NULL
Richman	NULL
.	NULL

1989	NULL
.	NULL

Interferons	NULL
and	NULL
bacterial	NULL
lipopolysaccharide	NULL
protect	NULL
macrophages	NULL
from	NULL
productive	NULL
infection	NULL
by	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
vitro	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

169:1137-1151	NULL
.	NULL

27	NULL
.	NULL

Lane	NULL
,	NULL
H.	NULL
C.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Kovacs	NULL
,	NULL
J.	NULL
Feinberg	NULL
,	NULL
B.	NULL
Herpin	NULL
,	NULL
V.	NULL
Davey	NULL
,	NULL
R.	NULL
Walker	NULL
,	NULL
L.	NULL
Deyton	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Metcalf	NULL
,	NULL
M.	NULL
Baseler	NULL
,	NULL
N.	NULL
Salzman	NULL
,	NULL
J.	NULL
Manischewitz	NULL
,	NULL
G.	NULL
Quinnan	NULL
,	NULL
H.	NULL
Masur	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1988	NULL
.	NULL

Anti-retroviral	NULL
effects	NULL
of	NULL
interferon-a	NULL
in	NULL
AIDS-associated	NULL
Kaposi	NULL
's	NULL
sarcoma	NULL
.	NULL

Lancet	NULL
ii:1218-1222	NULL
.	NULL

28	NULL
.	NULL

Larner	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
G.	NULL
Jonak	NULL
,	NULL
Y.-S.	NULL
Cheny	NULL
,	NULL
B.	NULL
Kornat	NULL
,	NULL
E.	NULL
Knight	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Darnell	NULL
,	NULL
Jr.	NULL
1984	NULL
.	NULL

Transcriptional	NULL
induction	NULL
of	NULL
two	NULL
genes	NULL
in	NULL
human	NULL
cells	NULL
by	NULL
B-interferon	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
81:6733-6737	NULL
.	NULL

29	NULL
.	NULL

Lenardo	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
C.-M	NULL
.	NULL

Fan	NULL
,	NULL
T.	NULL
Maniatis	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
involvement	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
B-interferon	NULL
gene	NULL
regulation	NULL
reveals	NULL
its	NULL
role	NULL
as	NULL
widely	NULL
inducible	NULL
mediator	NULL
of	NULL
signal	NULL
transduction	NULL
.	NULL

Cell	NULL
57:287-294	NULL
.	NULL

30	NULL
.	NULL

Levy	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
D.	NULL
S.	NULL
Kessler	NULL
,	NULL
R.	NULL
Pine	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Darnell	NULL
,	NULL
Jr.	NULL
1989	NULL
.	NULL

Cytoplasmic	NULL
activation	NULL
of	NULL
ISGF3	NULL
,	NULL
the	NULL
positive	NULL
regulator	NULL
of	NULL
interferon-alpha-stimulated	NULL
transcription	NULL
,	NULL
reconstituted	NULL
in	NULL
vitro	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

3:1362-1371	NULL
.	NULL

31	NULL
.	NULL

Levy	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
D.	NULL
S.	NULL
Kessler	NULL
,	NULL
R.	NULL
Pine	NULL
,	NULL
N.	NULL
Reich	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Darnell	NULL
,	NULL
Jr.	NULL
1988	NULL
.	NULL

Interferon-induced	NULL
nuclear	NULL
factors	NULL
that	NULL
bind	NULL
a	NULL
shared	NULL
promoter	NULL
element	NULL
correlate	NULL
with	NULL
positive	NULL
and	NULL
negative	NULL
transcriptional	NULL
control	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

2:383-393	NULL
.	NULL

32	NULL
.	NULL

Luckow	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
G.	NULL
Schutz	NULL
.	NULL

1987	NULL
.	NULL

CAT	NULL
constructions	NULL
with	NULL
multiple	NULL
unique	NULL
restriction	NULL
sites	NULL
for	NULL
the	NULL
functional	NULL
analysis	NULL
of	NULL
eukaryotic	NULL
promoters	NULL
and	NULL
Vou	NULL
.	NULL

69	NULL
,	NULL
1995	NULL
33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48.	NULL
regulatory	NULL
elements	NULL
.	NULL

Nucleic	NULL
Acid	NULL
Res	NULL
.	NULL

15:5490	NULL
.	NULL

Mosca	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
D.	NULL
P.	NULL
Bednarik	NULL
,	NULL
N.	NULL
B.	NULL
K.	NULL
Raj	NULL
,	NULL
C.	NULL
A.	NULL
Rosen	NULL
,	NULL
J.	NULL
G.	NULL
Sodroski	NULL
,	NULL
W.	NULL
A.	NULL
Haseltine	NULL
,	NULL
G.	NULL
S.	NULL
Hayward	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Pitha	NULL
.	NULL

1987	NULL
.	NULL

Activation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
by	NULL
herpesvirus	NULL
infection	NULL
:	NULL
identification	NULL
of	NULL
a	NULL
region	NULL
within	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
that	NULL
responds	NULL
to	NULL
a	NULL
trans-acting	NULL
factor	NULL
encoded	NULL
by	NULL
herpes	NULL
simplex	NULL
virus	NULL
1	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
84:7408-7412	NULL
.	NULL

Mosca	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Pitha	NULL
.	NULL

1986	NULL
.	NULL

Transcriptional	NULL
and	NULL
posttranscriptional	NULL
regulation	NULL
of	NULL
exogenous	NULL
human	NULL
beta	NULL
interferon	NULL
gene	NULL
in	NULL
simian	NULL
cells	NULL
defective	NULL
in	NULL
interferon	NULL
synthesis	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

6:2279-2283	NULL
.	NULL

Nabel	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1987	NULL
.	NULL

An	NULL
inducible	NULL
transcription	NULL
factor	NULL
activates	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
T-cells	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
326:711-713	NULL
.	NULL

Nabel	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
S.	NULL
A	NULL
.	NULL

Rice	NULL
,	NULL
D.	NULL
M.	NULL
Knipe	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1988	NULL
.	NULL

Alternative	NULL
mechanisms	NULL
for	NULL
activation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
enhancer	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Science	NULL
239:1299-1302	NULL
.	NULL

Ojwang	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
A.	NULL
Hampel	NULL
,	NULL
D.	NULL
J.	NULL
Looney	NULL
,	NULL
and	NULL
F.	NULL
Wong-Staal	NULL
.	NULL

1992	NULL
.	NULL

Inhibition	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
expression	NULL
by	NULL
a	NULL
hairpin	NULL
ribozyme	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:10802-10806	NULL
.	NULL

Osborn	NULL
,	NULL
L.	NULL
,	NULL
S.	NULL
Kunkel	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1989	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
and	NULL
interleukin	NULL
1	NULL
stimulate	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
enhancer	NULL
by	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
xB	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:2336-2340	NULL
.	NULL

Paya	NULL
,	NULL
C.	NULL
V.	NULL
,	NULL
R.	NULL
M.	NULL
Ten	NULL
,	NULL
C.	NULL
Bessia	NULL
,	NULL
J.	NULL
Alcami	NULL
,	NULL
R.	NULL
T.	NULL
Hay	NULL
,	NULL
and	NULL
J.-L.	NULL
Virelizier	NULL
.	NULL

1992	NULL
.	NULL

NF-	NULL
«	NULL
xB-dependent	NULL
induction	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
p50	NULL
subunit	NULL
gene	NULL
promoter	NULL
underlies	NULL
self-perpetuation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
transcription	NULL
in	NULL
monocytic	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89:7826-7830	NULL
.	NULL

Pitha	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
B.	NULL
Fernie	NULL
,	NULL
F.	NULL
Maldarelli	NULL
,	NULL
T.	NULL
Hattman	NULL
,	NULL
and	NULL
N.	NULL
A.	NULL
Wivel	NULL
.	NULL

1980	NULL
.	NULL

Effect	NULL
of	NULL
interferon	NULL
on	NULL
mouse	NULL
leukaemia	NULL
virus	NULL
(	NULL
MuLV	NULL
)	NULL
.	NULL

V.	NULL
Abnormal	NULL
proteins	NULL
in	NULL
virions	NULL
of	NULL
Rauscher	NULL
MuLV	NULL
produced	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
interferon	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

46:97-110	NULL
.	NULL

Poli	NULL
,	NULL
G.	NULL
,	NULL
J.	NULL
M.	NULL
Orenstein	NULL
,	NULL
A.	NULL
Kinter	NULL
,	NULL
T.	NULL
M.	NULL
Folks	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1989	NULL
.	NULL

Interferon-a	NULL
but	NULL
not	NULL
AZT	NULL
suppresses	NULL
HIV	NULL
expression	NULL
in	NULL
chronically	NULL
infected	NULL
cell	NULL
lines	NULL
.	NULL

Science	NULL
244:575-577	NULL
.	NULL

Pomerantz	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
and	NULL
M.	NULL
S.	NULL
Hirsch	NULL
.	NULL

1987	NULL
.	NULL

Interferon	NULL
and	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
infection	NULL
.	NULL

Interferon	NULL
9:113-127	NULL
.	NULL

Popik	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Pitha	NULL
.	NULL

1993	NULL
.	NULL

Role	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
in	NULL
activation	NULL
and	NULL
replication	NULL
of	NULL
fat-defective	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:1094-1099	NULL
.	NULL

Raj	NULL
,	NULL
N.	NULL
B.	NULL
K.	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Pitha	NULL
.	NULL

1981	NULL
.	NULL

Analysis	NULL
of	NULL
interferon	NULL
messenger	NULL
RNA	NULL
in	NULL
human	NULL
fibroblast	NULL
cells	NULL
induced	NULL
to	NULL
produce	NULL
interferon	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
78:7426-7430	NULL
.	NULL

Real	NULL
,	NULL
F.	NULL
X.	NULL
,	NULL
H.	NULL
F.	NULL
Oettgen	NULL
,	NULL
and	NULL
S.	NULL
E.	NULL
Krown	NULL
.	NULL

1986	NULL
.	NULL

Kaposi	NULL
's	NULL
sarcoma	NULL
and	NULL
the	NULL
acquired	NULL
immunodeficiency	NULL
syndrome	NULL
:	NULL
treatment	NULL
with	NULL
high	NULL
and	NULL
low	NULL
doses	NULL
of	NULL
recombinant	NULL
leukocyte	NULL
A	NULL
interferon	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Oncol	NULL
.	NULL

4544-551	NULL
.	NULL

Reich	NULL
,	NULL
N.	NULL
,	NULL
B.	NULL
Evans	NULL
,	NULL
D.	NULL
Levy	NULL
,	NULL
D.	NULL
Fahey	NULL
,	NULL
E.	NULL
Knight	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Darnell	NULL
,	NULL
Jr.	NULL
1987	NULL
.	NULL

Interferon-induced	NULL
transcription	NULL
of	NULL
a	NULL
gene	NULL
encoding	NULL
a	NULL
15-kDa	NULL
protein	NULL
depends	NULL
on	NULL
an	NULL
upstream	NULL
enhancer	NULL
element	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
84:6394-6398	NULL
.	NULL

Reich	NULL
,	NULL
N.	NULL
C.	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Darnell	NULL
,	NULL
Jr.	NULL
1989	NULL
.	NULL

Differential	NULL
binding	NULL
of	NULL
interferon-induced	NULL
factors	NULL
to	NULL
an	NULL
oligonucleotide	NULL
that	NULL
mediates	NULL
transcriptional	NULL
activation	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

17:3415-3424	NULL
.	NULL

Rosen	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
J.	NULL
G.	NULL
Sodroski	NULL
,	NULL
and	NULL
W.	NULL
A.	NULL
Haseltine	NULL
.	NULL

1985	NULL
.	NULL

The	NULL
location	NULL
of	NULL
cis-acting	NULL
regulatory	NULL
sequences	NULL
in	NULL
the	NULL
human	NULL
T	NULL
cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
SELECTIVE	NULL
EXPRESSION	NULL
OF	NULL
A	NULL
TRANSDUCED	NULL
IFN	NULL
GENE	NULL
49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

121	NULL
II	NULL
(	NULL
HTLV-III/LAV	NULL
)	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

Cell	NULL
41:813-823	NULL
.	NULL

Ross	NULL
,	NULL
E.	NULL
K.	NULL
,	NULL
A.	NULL
J.	NULL
Buckler-White	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Rabson	NULL
,	NULL
G.	NULL
Englund	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Martin	NULL
.	NULL

1991	NULL
.	NULL

Contribution	NULL
of	NULL
NF-kB	NULL
and	NULL
Sp1	NULL
binding	NULL
motifs	NULL
to	NULL
the	NULL
replicative	NULL
capacity	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
:	NULL
distinct	NULL
patterns	NULL
of	NULL
viral	NULL
growth	NULL
are	NULL
determined	NULL
by	NULL
T-cell	NULL
types	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:4350-4358	NULL
.	NULL

Sakaguchi	NULL
,	NULL
M.	NULL
,	NULL
B.	NULL
Zenzie-Gregory	NULL
,	NULL
J.	NULL
E.	NULL
Groopman	NULL
,	NULL
S.	NULL
T.	NULL
Smale	NULL
,	NULL
and	NULL
S.	NULL
Kim	NULL
.	NULL

1991	NULL
.	NULL

Alternative	NULL
pathway	NULL
for	NULL
induction	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
gene	NULL
expression	NULL
:	NULL
involvement	NULL
of	NULL
the	NULL
general	NULL
transcription	NULL
machinery	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:5448-5456	NULL
.	NULL

Sambrook	NULL
,	NULL
J.	NULL
,	NULL
E.	NULL
F.	NULL
Fritsch	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1989	NULL
.	NULL

Molecular	NULL
cloning	NULL
:	NULL
a	NULL
laboratory	NULL
manual	NULL
.	NULL

2nd	NULL
ed	NULL
.	NULL

,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
N.Y.	NULL
Sarver	NULL
,	NULL
N.	NULL
,	NULL
E.	NULL
M.	NULL
Cantin	NULL
,	NULL
P.	NULL
S.	NULL
Chang	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Zaia	NULL
,	NULL
P.	NULL
A.	NULL
Ladue	NULL
,	NULL
D.	NULL
A.	NULL
Stephens	NULL
,	NULL
and	NULL
J.	NULL
J.	NULL
Rossi	NULL
.	NULL

1990	NULL
.	NULL

Ribozymes	NULL
as	NULL
potential	NULL
anti-HIV-1	NULL
therapeutic	NULL
agents	NULL
.	NULL

Science	NULL
247:1222-1225	NULL
.	NULL

Schreck	NULL
,	NULL
R.	NULL
,	NULL
P.	NULL
Rieber	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
.	NULL

1991	NULL
.	NULL

Reactive	NULL
oxygen	NULL
intermediates	NULL
as	NULL
apparently	NULL
widely	NULL
used	NULL
messengers	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
transcription	NULL
factor	NULL
and	NULL
HIV-1	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

10:2247-2258	NULL
.	NULL

Sen	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1986	NULL
.	NULL

Inducibility	NULL
of	NULL
«	NULL
immunoglobulin	NULL
enhancer-binding	NULL
protein	NULL
NF-	NULL
«	NULL
B	NULL
by	NULL
a	NULL
posttranslational	NULL
mechanism	NULL
.	NULL

Cell	NULL
47:921-928	NULL
.	NULL

Shirazi	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Pitha	NULL
.	NULL

1992	NULL
.	NULL

Alpha	NULL
interferon	NULL
inhibits	NULL
carly	NULL
stages	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
replication	NULL
cycle	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66	NULL
:	NULL
1321-1328	NULL
.	NULL

Southgate	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
and	NULL
M.	NULL
R.	NULL
Green	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
HIV-1	NULL
Tat	NULL
protein	NULL
activates	NULL
transcription	NULL
from	NULL
an	NULL
upstream	NULL
DNA-binding	NULL
site	NULL
:	NULL
implications	NULL
for	NULL
Tat	NULL
function	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

5:2496-2507	NULL
.	NULL

Stein	NULL
,	NULL
B.	NULL
,	NULL
H.	NULL
J.	NULL
Rahmsdorf	NULL
,	NULL
A.	NULL
Steffen	NULL
,	NULL
M.	NULL
Litfin	NULL
,	NULL
and	NULL
P.	NULL
Herrlich	NULL
.	NULL

1989	NULL
.	NULL

UV-induced	NULL
DNA	NULL
damage	NULL
is	NULL
an	NULL
intermediate	NULL
step	NULL
in	NULL
UV-induced	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
,	NULL
collagenase	NULL
,	NULL
c-fos	NULL
,	NULL
and	NULL
metallo-thionein	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

95169-5181	NULL
.	NULL

Twu	NULL
,	NULL
J.-S.	NULL
,	NULL
and	NULL
W.	NULL
S.	NULL
Robinson	NULL
.	NULL

1989	NULL
.	NULL

Hepatitis	NULL
B	NULL
virus	NULL
X	NULL
gene	NULL
can	NULL
transactivate	NULL
heterologous	NULL
viral	NULL
sequences	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:2046-2050	NULL
.	NULL

Urban	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
65-kD	NULL
subunit	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
a	NULL
receptor	NULL
for	NULL
IxB	NULL
and	NULL
a	NULL
modulator	NULL
of	NULL
DNA-binding	NULL
specificity	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

41975-1984	NULL
.	NULL

Vlach	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Pitha	NULL
.	NULL

1992	NULL
.	NULL

Activation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
provirus	NULL
in	NULL
T	NULL
cells	NULL
and	NULL
macrophages	NULL
is	NULL
associated	NULL
with	NULL
induction	NULL
of	NULL
inducer-specific	NULL
NF-kB	NULL
binding	NULL
proteins	NULL
.	NULL

Virology	NULL
187:63-72	NULL
.	NULL

Vlach	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
P.	NULL
M.	NULL
Pitha	NULL
.	NULL

1992	NULL
.	NULL

Herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1-mediated	NULL
induction	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
provirus	NULL
correlates	NULL
with	NULL
binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
to	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
enhancer	NULL
and	NULL
leader	NULL
sequence	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:3616-3623	NULL
.	NULL

Yamamoto	NULL
,	NULL
J.	NULL
K.	NULL
,	NULL
F.	NULL
Barre-Sinoussi	NULL
,	NULL
V.	NULL
Bolton	NULL
,	NULL
N.	NULL
C.	NULL
Pedersen	NULL
,	NULL
and	NULL
M.	NULL
B.	NULL
Gardner	NULL
.	NULL

1986	NULL
.	NULL

Human	NULL
alpha-	NULL
and	NULL
beta-interferon	NULL
but	NULL
not	NULL
gamma	NULL
suppress	NULL
the	NULL
in	NULL
vitro	NULL
replication	NULL
of	NULL
LAV	NULL
,	NULL
HTLV-III	NULL
,	NULL
and	NULL
AKV-2	NULL
.	NULL

J.	NULL
Interferon	NULL
Res	NULL
.	NULL

6:142-152	NULL
.	NULL

Zabel	NULL
,	NULL
U.	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
.	NULL

1990	NULL
.	NULL

Purified	NULL
human	NULL
IxB	NULL
can	NULL
rapidly	NULL
dissociate	NULL
the	NULL
complex	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
transcription	NULL
factor	NULL
with	NULL
its	NULL
cognate	NULL
DNA	NULL
.	NULL

Cell	NULL
61:255-265	NULL
.	NULL

